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1.1 ABSTRACT 
 
The thesis primarily addresses the role of transcriptional corepressor and signal transduction cascades in regulating 
androgen receptor (AR) activity. AR is a ligand-activated transcription factor and is important for the development of 
male phenotype. Malfunctioning of AR function has been implicated in the progression of the prostate cancer (CaP). 
Clinical management of the CaP most often involves the administration of anti-hormones (Cas, CPA) that bind to AR 
and turn it transcriptionally incompetent and consequently regression of the tumor. Eventually though emerges 
resistance to therapy 3-4 semesters post-treatment but unfortunately modern medicine doesn’t offer any cure at this 
point. To safeguard the AR function, corepressor molecules negatively modulate AR function on its target genes 
hence suggested to have protective role against the CaP. Gene regulation by AR and corepressors can be influenced by 
activated signal transduction machinery often abruptly activated in CaP cells.  
The work pursued here in part shows how partial agonist CPA modulates the expression of target genes PSCA and 
Maspin. It also highlights how interaction of corepressor SMRT is modulated by signal transduction pathways in vivo. 
The work demonstrates the role of Src kinase pathway in regulating AR function in androgen-independent CaP cells. 
Inhibiting Src by chemical inhibitor PP2, leads to decrease in AR recruitment on target genes in vivo. Also it decreases 
transactivation potential of AR on various target genes. The work also shows that inhibition of Src leads to loss of 
target gene induction in response to agonist and growth retardation of C4-2, hormone-independently growing cells.  
This work also demonstrates the discovery of a new AR corepressor LCoR. Corepressor LCoR potently represses AR 
transactivation not only in anti-hormone but also in a hormone-dependent manner in CV1 cells. Versatility in 
repression by LCoR evidenced from the experiments showing potent in vivo repression of AR T877A hot spot mutant 
and another AR mutant which does not interact and thereby not repressed by many other corepressors. This work also 
shows that for its interaction with AR LCoR uses its C-terminus, which harbours HLH domain that interacts with the 
DBD of AR in vivo. Intriguingly LCoR shows only marginal repression of endogenous AR in CaP cells. This work 
shows that LCoR is functionally weakened by Src kinase pathway in CaP cells in repressing AR function. Inhibition 
of Src by Src inhibitor PP2 enhances autonomous silencing function of LCoR. In addition, this inhibition by PP2 
enhances its ability to interact and thereby repress AR in CaP.  Overexpression of stably-integrated corepressor LCoR 
in CaP cells leads to compromised growth.  
This work demonstrates the importance of molecular cross talk between corepressors and signal transduction pathways 
that functionally modulate the corepressor function and thereby regulate AR transactivation and growth of CaP. It also 
opens an important avenue in translational cancer research implicating the role of cross talk between signaling 
cascades and corepressors in CaP. 
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1.2 ZUSAMMENFASSUNG 
 
 
In dieser Arbeit wurde die Bedeutung transkriptionaler Corepressoren und der Signaltransduktions-Kaskade bei der 
Regulation des Androgen-Rezeptors (AR) untersucht. Der AR ist ein durch Liganden aktivierbarer 
Transkriptionsfaktor und ist für die Entwicklung des männlichen Phänotyps von großer Bedeutung. Dysfunktionen des 
AR sind mit der Progression von Prostata-Krebs (CaP) assoziiert. Das klinische Management bei der Behandlung von 
CaP besteht häufig in der Gabe von Anti-Hormonen (Cas, CPA), welche an den AR binden, dessen Transkription 
unterbinden und daher zu einer Regression des Tumors führen. Nach 1-2 Jahren der Therapie mit Anti-Hormonen 
kommt es meist zu einer Therapie-Resistenz, die leider zum jetzigen Zeitpunkt keine medizinische Heilung 
ermöglicht. Corepressoren, die den AR transkriptionell hemmen, scheinen daher eine hemmende Rolle bei der CaP-
Proliferation zu haben. In CaP-Zellen kann die Genregulation durch AR und Corepressoren durch eine Aktivierung der 
Signalkaskade beeinflusst werden.  
In dieser Arbeit wurde untersucht, wie der partielle Agonist CPA die Expression der Zielgene PSCA und Maspin 
reguliert. Es wurde weiterhin analysiert, wie eine Interaktion des Corepressors SMRT durch Signalwege in vivo 
moduliert wird. Die Arbeit zeigt die Bedeutung des Src-Kinase-Signalweges bei der Regulation der AR-Funktion in 
Androgen-unabhängigen CaP-Zellen. Wird Src durch den chemischen Inhibitor PP2 blockiert, führt dies in vivo zu 
einer verminderten AR-Rekruitierung an Ziel-Genen. Auch das Transaktivierungspotential von AR an verschiedenen 
Ziel-Genen ist vermindert. In dieser Arbeit wurde weiterhin gezeigt, dass eine Inhibierung von Src zu einem Verlust 
der Induktion der Zielgene als Antwort auf den Agonisten und zu einem verminderten Wachstum der C4-2-Zellen, 
einer Hormon-unabhängig wachsende Zelllinie, führt.  
Weiterhin wurde in dieser Arbeit LCoR als ein neuer Corepressor für den AR beschrieben. Der Corepressor LCoR 
unterdrückt die AR-Transaktivierung sowohl durch Anti-Hormone als auch durch Hormone in CV-1-Zellen. Die 
Vielseitigkeit der Repression von LCoR wurde in Experimenten gezeigt, die eine effektive in vivo Hemmung der AR 
T877A „hot spot“-Mutante und anderer AR-Mutanten zeigen. Diese können mit vielen anderen Corepressoren nicht 
interagieren und somit nicht reprimiert werden. Das konnte auch nachgewiesen werden für die Interaktion des AR mit 
dem C-terminalen Ende von LCoR mit einer HLH-Domäne, welche mit der DBD-Domäne des AR in vivo reagiert. 
Interessanterweise zeigte LCoR nur eine geringe Repression des endogenen ARs in CaP-Zellen. In dieser Arbeit 
wurde auch gezeigt, dass durch den Src-Signalweg in CaP-Zellen LCoR funktionell schwächer wird. Eine Hemmung 
von Src durch den Src-Inhibitor PP2 führt zu einer Verstärkung der Funktion von LCoR. Darüber hinaus fördert diese 
Inhibierung durch PP2 eine Interaktion und führt zu einer Unterdrückung der AR-Transaktivierung in CaP-Zellen. Die 
Überexpression von stabil integrierten LCoR in CaP-Zellen führt zu einer Beeinträchtigung des Wachstums.  
Diese Arbeit zeigt die Bedeutung des molekularen „cross talks“ zwischen Corepressor und Signaltransduktions-
Wegen, welche die Funktion des Corepressors funktionell moduliert, dadurch die AR-Aktivierung und die 
Proliferation von Prostata-Tumoren reguliert. Für weitere Forschungen könnten möglicherweise die Erkenntnisse 
bezüglich des „cross talks“ zwischen Signalkaskaden und Corepressoren in Hinblick auf die Prostata-Tumoren genutzt 
werden.
INTRODUCTION 
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INTRODUCTION 
 
2.1 Androgens and anti-androgens 
 
Androgens mediate a wide range of developmental and physiological responses. 
Androgens are steroid hormones that induce the differentiation and maturation of male 
reproductive organs (Cooke et al., 1991). They are major regulators of cell proliferation 
and cell death in the prostate gland (Isaacs, 1984). Production of androgens occurs in the 
endocrine glands, primarily in the testes and adrenal gland (Coffey and Isaacs 1981). In 
prostate, testosterone (a major androgen) is converted to 5 α-dihydrotestosterone (DHT) by 
5 α-reductase activity (Russell and Wilson 1994). The androgens have been shown to 
regulate the expression of many target genes. For example, the expression of prostate 
specific antigen (PSA) is androgen-regulated (Young et al., 1992, Perry et al., 1996). The 
connection between androgen action and cell growth control may be explained by the fact 
that the androgens also regulate several genes involved in cell cycle control, such as cyclin-
dependent kinase inhibitors p16 and p21 and cyclin-dependent kinases 2 and 4 (Lu et al., 
1997, 1999). Androgens are believed to have, at least, a permissive role in the genesis of 
CaP as castration of a male before puberty inhibits the growth of the prostate and prevents 
the initiation of CaP (Isaacs, 1994; Moore 1944). 
 
2.2 The nuclear receptor (NR) superfamily  
 
The mammalian nuclear receptor superfamily comprises more than 45 transcription factors, 
many of which regulate gene expression in a ligand-dependent fashion (Perissi and 
Rosenfeld, 2005). The nuclear receptors mediate the actions of lipid-soluble steroid 
hormones and nonsteroidal lipophilic hormones. There are also several nuclear “orphan 
receptors” whose regulatory ligands have not yet been identified (Giguere 1999). The 
ligands of different nuclear receptors are diverse, but the receptors are structurally quite 
similar to each other (Mangelsdorf et al., 1995). Also a subset of receptors, which includes 
receptor for thyroid hormone (TR) and Retinoic Acid Receptor (RAR), can actively repress 
target genes in the absence of ligand, whereas upon binding to cognate ligand almost in all 
cases the receptors usually become potent transcriptional activators. Conversely, several 
NRs have been shown to inhibit transcription in a ligand-dependent manner either by 
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binding to negative response elements or by antagonizing the transcriptional activities of 
other classes of transcription factors (Weston et al., 2003 and Nettles et al., 2004). 
The nuclear receptors are cytosolic or nuclear proteins and the activation of the steroid 
receptor from an inactive, chaperone-protein bound state requires the binding of the 
cognate ligand, which induces a conformational change in the receptor structure. This leads 
to the dissociation of chaperone proteins, receptor dimerization and nuclear shuttling 
(Moras and Gronemeyer 1998). In the nucleus, a dimerized receptor complex regulates the 
transcription of the target genes by binding to cognate response element in DNA. There are 
however some exceptions to this basic model of NR function as in case of Ecdysone 
receptor, which is predominantly nuclear in nature (Koelle et al., 1991). In addition, 
nuclear receptors can mediate the so-called non-genomic, DNA binding independent 
effects of hormones in the cells (Peterziel et al., 1999). 
The nuclear receptor family can be divided into subgroups according to the pattern by 
which they bind to the ligand, to DNA and to each other. Class I, the steroid receptor 
subfamily, consists of androgen (AR), estrogen (ER), progesterone (PR), glucocorticoid 
(GR) and mineralocorticoid (MR) receptors. There are receptors that bind diverse products 
of lipid metabolism such as fatty acids and prostaglandins (peroxisome proliferator 
activated receptors, PPARs and liver X receptors, LXR) (Aranda and Pascual, 2001 and 
Gronemeyer et al., 2004).  
The modular structure of the NHRs consists of three different functional domains: a 
variable amino-terminal domain, the central well-conserved DNA binding domain, and the 
moderately conserved carboxy-terminal ligand binding domain, separated from each other 
by hinge regions (MacLean et al., 1997). 
 
2.2.1 The Androgen receptor: Genomic effects 
 
The human androgen receptor (AR) gene, located in the chromosome Xq11-12, contains 8  
 
 
 
 
 
Fig. 2.1 The modular structure of AR. AR is 919 a.a. member of nuclear hormone receptor 
superfamily containing N-terminus transactivation domain (NTD), a DNA-binding domain (DBD), 
hinge region (HR) and Ligand-binding domain (LBD). NTD contains a hormone-independent 
activation function (AF1) and another activation function called, transactivation unit 5 (TAU-5), 
NTD                              DBD  HR                             LBD
AF1 TAU5 AF2
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and a ligand-dependent activation function (AF2) situated in the LBD. Both of NTD and LBD 
contribute to transactivation function. 
 
exons (Lubahn et al., 1988). The AR gene is almost universally expressed in different 
tissues (Faber et al., 1991). AR mediates the biological effects of androgens. Structurally, 
AR can be subdivided into three well-defined functional domains: the amino terminus 
transactivation domain (NTD), the DBD, hinge region and the LBD (Fig. 2.1). The 
transactivation by AR involves the NTD which harbours AF1 and TAU-5 transactivation 
functions that can act in a ligand-independent manner. AF1 (activation function 1), 
functions in a ligand-independent manner when artificially separated from the LBD; the 
AR NTD mutant therefore lose their transactivation potential (Jenster et al., 1995). TAU-5 
is activated by PRK1 signal transduction pathway and has been implicated in CaP 
progression (Metzger et al., 2003). NTD has also been shown to be the target of 
corepressor-mediated receptor repression (Dotzlaw et al., 2002). The NTD also contains a 
few homopolymeric amino acid repeats typical for many transcription factors. The most 
amino-terminal repeat is the polyglutamine (Q) repeat, coded by CAG triplets. Like other 
genes with the CAG repeats, the repeat length is very polymorphic, ranging from 14 to 35 
(Sartor et al., 1999). Lengthening the repeat to 40-62 suggested to be involved in an 
inherited neuromuscular degenerative disease, Kennedy’s disease or spinal and bulbar 
muscular atrophy, SBMA (La Spada et al., 1991).  
Many coactivators such as SRC1 family of coactivators are known to interact with this 
sequence in an agonist-dependent manner to promote transcription (Ma et al., 1999). The 
amino acid sequence of DBD is a most highly conserved among members of the nuclear 
receptor superfamily. It includes zinc fingers, in which four cysteine residues bind one zinc 
ion in each of the motifs. The zinc fingers have been shown to be fundamental to the 
binding of the response element in DNA (O’Malley 1990). The first zinc finger harbors the 
information for the specific recognition of DNA, and the second finger stabilizes the DNA-
receptor interaction in contact with the DNA backbone and has been shown to be involved 
in interaction with other coregulatory molecules (Glass 1994).  
The third domain structure in the AR is the carboxy-terminal ligand binding domain. It 
contains the ligand-dependent transactivation function AF2 which is responsible for 
optimal transcription activation in response to the ligand. Both the N-terminal 
transactivation domain and the LBD are responsible for and coordinate the ligand-
dependent transactivation function of the NRs (Tora et al., 1989). The N-terminal 
activation function (AF1) is constitutively active on its own, while the AF2 function in the  
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LBD is induced upon ligand binding. Because the transactivation function is normally 
androgen-dependent, the LBD prevents the action of the receptor without the ligand (Kuil 
and Brinkmann 1996). Deletions in this domain abolish the binding and response of 
androgens, which results in a constitutively active AR (Jenster et al., 1991). The activities 
of both activation functions are dependent on the cell type and promoter context (Beato et 
al., 1995). The N terminus transactivation domain and C terminus LBD of AR are known 
to interact with each other and this interaction has been shown to contribute to the optimal 
activation of the AR (He et al., 2000).  
Like few other members of NR superfamily, unbound AR is inactive and forms a complex 
with chaperones/HSPs (Heat shock proteins) in the cytoplasm (Georget et al., 1997; Jenster 
et al., 1991). The binding of androgens to AR induces a conformational change that leads 
to dissociation of AR from the HSPs and subsequent receptor dimerisation and 
translocation into the nucleus, facilitating the ability of AR to bind to its cognate response 
elements, called AREs (androgen response elements) in the target genes (Claessens et al., 
2001; Roche et al., 1992), recruit coregulators to modulate the expression of the target 
genes (Collingwood et al., 1999; Glass and Rosenfeld, 2000; Xu et al., 1999). 
 
2.2.2 The androgen receptor: Non-genomic effects 
 
The androgens can exert effects, which are considered to be non-genomic (rapid effects) 
because these effects take place in the presence of transcription inhibitors or they are 
occurring too fast to involve changes in gene transcription. Until now, the reported non-
genomic effects of the steroids at physiological concentrations appear to be receptor-
mediated (Heinlein and Chang 2002). The non-genomic actions include stimulation of 
MAPK (mitogen-activated protein kinase) pathway and induction of cAMP second 
messenger and PKA (protein kinase A) by androgens. Both of these mechanisms also 
influence the transcriptional activation of the nuclear AR (Peterziel et al., 1999 and Cato et 
al., 2002). In addition, the existence of a novel, cell membrane bound androgen receptor 
has been suggested (Benten et al., 1999) but remains to be identified. One of the effects 
mediated by this putative receptor is the increase of intracellular calcium levels, which in 
turn could be able to activate signal transduction cascades such as the PKA, PKC (protein 
kinase C) and MAPK or to modulate the activity of the transcription factors. Androgen-
mediated modulation of the ion channel activity and intracellular calcium levels has been 
observed in several cell types (Heinlein and Chang 2002) including LNCaP cells 
(Steinshapir et al., 1991). However, it has not yet been determined whether these non-
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genomic effects are mediated through a membrane androgen receptor or by steroid 
hormone transporter proteins termed as steroid hormone binding globulin or SHBGs. 
 
2.3 Coregulatory proteins of AR 
 
 AR activates the expression of the target genes by facilitating transcriptional. AR-
mediated transcription requires several auxiliary protein complexes (Hermanson et al., 
2002) that can interact sequentially, in combination or in parallel such as coactivators and 
corepressors. Coactivators are generally recruited to agonist-bound AR e.g., coactivator 
p300 contains HAT activity and can alter the architecture of chromatin to facilitate 
transcription. Histone acetylation neutralizes the positive charge of the histone N-terminal 
tails and weakens the interaction between histones and negatively charged DNA. Thus, the 
recruitment of chromatin remodeling proteins and acetyltransferases is essential to make 
the target sequences accessible for the liganded receptor. Conversely, corepressors 
complexes often contain HDACs, leading to deacetylation of the histone tails, leading to 
condensed chromatin structure resulting in transcriptional repression (Burke and 
Baniahmad, 2000 and Hu and Lazar 2000). Recently, another AR coactivator, Lysine-
specific demethylase was identified. It interacts with the AR in a ligand-dependent fashion 
and its knock down in LNCaP cells leads to abrogation of cell proliferation (Metzger et al., 
2005). 
 
2.3.1 Corepressors 
 
Nuclear receptor corepressors were originally identified as proteins associated with 
unliganded type II nuclear receptors which, unlike type I nuclear receptors, can bind to 
DNA in the absence of a ligand and mediate transcriptional repression (Horlein et al., 
1995). Retinoic acid receptor and thyroid hormone receptor are capable of gene repression 
by interacting with the corepressors and recruiting the HDAC activities, whereas the 
steroid receptors, including the AR, do not repress transcription in the absence of a ligand 
(Hu and Lazar 2000). For the ER, the switch from gene activation to gene repression by an 
antagonist is accomplished by association of the corepressors and HDACs (Shang et al., 
2002). Due to the structural and functional similarities between the ER and AR, it has been 
proposed that the corepression complex may be similarly recruited by antagonist-bound 
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AR (Shang et al., 2002). Indeed Dotzlaw et al., (2002) have shown the in vivo binding of 
corepressor SMRT to anti-hormone CPA-bound AR. 
Different corepressors are known to act by targeting various domains of AR. The 
corepressor calreticulin for example functions by associating with the DBD of AR and 
inhibits AR binding to its DNA response elements leading to target gene repression. 
(Dedhar et al., 1994) interestingly   calreticulin   has    been   identified    as   an  androgen-  
 
 
 
 
 
Fig. 2.2 Typical structure of a corepressor. It essentially harbours a CoRNR motif with 
consensus LXX/HIXXXI/L for its interaction with the nuclear receptor. In addition has repression 
domain(s) by which it can recruit gene silencing machinery to the receptor thereby inhibiting 
transcription initiation. 
 
responsive gene in prostate suggesting a feedback control (Zhu et al., 1998). Other kinds of 
corepressors recruit histone deacetylases (HDACs) to silence gene expression. HDACs 
play a critical role in altering the acetylation status of core histones leading to deacetylation 
thereby making chromatin to adopt a condensed conformation inhibitory to transcription by 
AR as well as by other transcription factors (Grunstein et al., 1997, Xu et al., 1999). 
Corepressor SMRT (Silencing Mediator for RAR and TR), Alien and NCoR (Nuclear 
receptor corepressor) are the exemplary of those and are known to be recruited to 
numerous NRs. (Ordertlich et al., 2001, Chen and Evans 1995, Horlein et al., 1995, Dressel 
et al., 1999). Indeed SMRT and NCoR have been shown to attenuate AR transactivation 
through competing for interaction between AR and its coactivators. Inhibition of target 
genes by corepressor Alien has been shown to be Trichostatin A (TSA) (HDAC inhibitor) 
sensitive and can functionally interact with other molecules of the signaling machinery like 
mSinA (Moehren et al., 2004). This interaction might have synergistic effect in repressing 
AR function. This suggests that inhibition of AR activity involves recruitment of 
corepressors in the form a repression complexes with other transcription inhibitory 
proteins. Similarly a SMRT (Silencing Mediator for RAR and TR)/HDAC complex has 
been shown to contain nuclear receptor corepressor, NCoR (Li et al., 2000). Another class 
of corepressors interrupt the interaction between AR and its coactivators e.g., Cyclin D1 
which suppresses transactivation by AR (Knudsen et al., 1999). The C-terminal domain of 
cyclin D1 and the hinge region of AR mediate AR-cyclin D1 interaction. Furthermore, 
Repression domain            Interaction domain (CoRNR box)
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cyclin D1 inhibition of AR may result from its capacity to inhibit the association of 
coactivator P/CAF and AR (Reutens et al., 2001). Complexity is further added by 
corepressors that can interrupt the interaction between the NTD and LBD of AR (often 
called N-C interaction). A key checkpoint Rad family protein, called hRad9 was recently 
identified as a corepressor for AR in CaP cells. The LBD of AR can interact with the CTD 
of the hRad9. The FXXLF motif within the CTD of hRad9 interrupts the DHT induced AR 
N-C terminus interaction. This interaction between AR and Rad9 results in the suppression 
of AR transactivation (Wang et al., 2004). Another corepressor Alien (Dressel et al., 1999) 
has been identified previously for TR. Recent data suggest that Alien can be recruited to 
CPA-bound AR. Stable integration of the corepressor Alien in CaP cells leads to inhibition 
of LNCaP cell growth in a CPA-dependent manner (Moehren et al., Communicated). The 
ability of the corepressor to inhibit CaP growth suggests that corepressor inactivation plays 
an important role in the progression of CaP. 
 
2.3.2 The agonist-dependent corepressors: LCoR 
 
Hormone binding, particularly by NHRs is widely associated with activation of the target 
gene transcription by the recruitment of coactivators that contain LXXLL motif (called NR 
box). Corepressors, such as SMRT and NCoR recognize LBDs in a hormone free or, in 
some cases, antagonist-bound conformation as for AR (Dotzlaw et al., 2002). However, a 
model of receptor activation where only coactivators are recruited to agonist-bound 
receptors can not entirely explain the existence of large number of corepressor identified to 
date. Indeed several NR box-containing corepressor proteins have been identified e.g., 
TIF1α, (Le Douarin et al., 1995). A similar SET domain containing protein NR-binding 
SET-domain-containing protein (NSD1) contains both NR boxes and CoRNR motifs 
similar to those of SMRT and NCoR. These motifs control its interaction with multiple 
NRs in either a ligand-dependent or -independent fashion (Huang et al., 1998). NSD1 
contains several distinct coactivation and corepression domains, raising the possibility that 
their functions may be selectively modulated by secondary signal transduction pathways, 
thus controlling whether NSD1 acts as a coactivator or a corepressor. 
Receptor interacting protein (RIP140) was initially characterized as a coactivator 
(Cavailles et al., 1995) that interacts through multiple NR boxes with ER. Later work 
however showed that RIP140 functions as a corepressor that competes with coactivator 
p160 for binding to agonist-bound LBDs of NHRs, blocking coactivation in vivo. (Eng et 
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al., 1998, Lee et al., 1998, Treuter et al., 1998). RIP140 was reported to inhibit AR-
dependent transactivation in agonist-dependent manner (Christian et al., 2006).  
Recently also, a ligand-dependent corepressor, LCoR, was identified in a screen for 
proteins that interacted with the LBD of ERα in an estradiol-dependent manner (Fernandes 
et al., 2003) LCoR represses ligand-dependent transactivation of PR, GR, VDR and ER. In 
order to interact with them uses the single NR box having LXXLL motif. Therefore, the 
LCoR NR box mutant shows loss of interaction with these NHRs (Fernandes et al., 2003) 
and  thereby  receptor  repression  is  abolished.  LCoR  binds to the same coactivator p160  
 
 
 
 
 
 
 
Fig. 2.3 Schematic representation of the primary structure of LCoR. The NR box is 
represented by black bar. Positions of CtBP binding motifs are indicated by white boxes. HDAC 
binding domains are over lined. (Fernandes et al., 2003) 
 
 binding pocket of NHRs (Fernandes et al., 2003) suggesting that it competes with 
coactivators for recruitment to selected members of NHRs superfamily. LCoR is described 
as molecular scaffolds for many transcriptional repressors (White et al., 2004). 
Corepression of ER and GR can be blocked by HDAC inhibitor TSA, however, that of 
VDR and PR remained unaffected by TSA treatment suggesting LCoR functions in 
HDAC-dependent and -independent manner. In fact, LCoR interacts directly with HDACs 
3 and 6 but not with 2 and 4 in vitro and in vivo (Fernandes et al., 2003). Agonist-
dependent corepressors have been shown to possess CtBP corepressor binding motifs (Fig. 
2.3) and mutation of this binding motif severely attenuates their corepressor function as in 
case of RIP140. Remarkably the sequence of LCoR revealed also the presence of tandem 
motifs PLDLTVR and VLDLSTK that are homologous to the consensus P/VLDLS/TXK/R 
defined as a binding site for CtBPs (Vo et al., 2001) in vitro binding and Co-IP studies 
revealed that the CtBP binding is disrupted only upon mutations in both sites (Fernandes et 
al., 2003). Immuno-cytochemical studies revealed a substantial overlap of CtBPs and 
LCoR in discrete nuclear bodies (Fernandes et al., 2003). 
The binding of CtBPs may explain the observation that the sensitivity of corepressor LCoR 
to the HDAC inhibitor is receptor-dependent. While transcriptional repression of ERα and 
1 433
PLDLTVR     VLDLSTK
HDACs
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GR has been shown to be TSA sensitive, the repression of PR and VDR was largely TSA 
resistant (White et al., 2003). Furthermore, corepression of ERα was partially disrupted by 
the mutations of the CtBP motifs of the LCoR, corepression of PR function was completely 
released by the same mutations. This suggests that mode of repression by LCoR is largely 
dependent on the promoter context same as for CtBP (Chinnadurai 2002). 
 
2.4 Androgen receptor in prostate cancer 
 
Several alterations take place in the AR signaling pathway during the development and 
progression of prostate cancer. First, the action of the AR in a normal and malignant 
prostate uses distinct pathways. In a normal prostate gland, androgen-stimulated 
proliferation of epithelium requires paracrine involvement of stromal cells expressing the 
AR. In malignant cells the androgen-mediated signaling has been converted to autocrine 
mode and no interaction with the stroma is needed (Gao et al., 2001). In addition, the 
emergence of the hormone-refractory tumors during the antihormone-therapy is associated 
by restoration of the expression of the genes regulated by the AR (Gregory et al., 2001, 
Kim et al., 2002) such as PSA. It is noteworthy, that hormone-refractory CaP cells though 
grow in a hormone-dependent manner, they still depend on functional AR signaling for 
growth and their growth is severely compromised if AR is depleted in cells using RNAi. 
(Chen et al., 2004 ; Liao et al., 2005; Haag et al., 2005). Many changes that lead to aberrant 
AR signaling are believed to be caused at least partly by genetic changes in the AR gene. 
 
2.4.1 Germ-line alterations 
 
It has been suggested that a short CAG repeats in the NTD of AR may result in an 
increased risk of prostate cancer and that the length of the repeat could also be partly 
responsible for the difference in prostate cancer risk in different racial groups (Edwards et 
al 1992 and Irvine et al., 1995). For example, Giovannucci et al., (1997) observed that the 
shorter repeat was associated with an increased risk for metastatic and fatal prostate cancer.  
 
2.4.2 Somatic aberrations of AR in androgen-dependent prostate cancer 
 
Studies have indicated only a few somatic mutations of the AR in untreated prostate cancer 
(Newmark et al., 1992, Suzuki et al., 1993, Culig et al., 1993, Ruizeweld de Winter et al., 
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1994). However, mutations are present in a substantial fraction of prostate cancers. 
Gaddipati and co-authors (1994) reported that a codon T877A mutation was found in 25% 
of the patients with untreated metastatic prostate cancer. However, it is now generally 
accepted that the AR mutations are rare in untreated prostate cancer. 
 
2.4.3 Somatic aberrations of AR gene in hormone-refractory prostate cancer 
 
AR gene amplification 
 
A high-level AR amplification in 30% of the hormone-refractory tumors but not in the 
specimens taken from the same patients prior to therapy (Visakorpi et al., 1995 and 
Bubendorf et al., 1999), found the AR gene amplification in 23% of the 54 locally 
recurrent and 22% of the 62 metastases of hormone-refractory disease. The findings 
suggest that the amplification of the AR gene may be one of the mechanisms by which the 
prostate tumors acquire growth advantage in an androgen-depleted environment. The 
amplification of the AR may sensitize the prostate cancer cells to trace amounts of the 
androgens (Visakorpi et al., 1995, Culig et al., 1997).  
 
AR gene mutations 
 
One of the best studied mutations in hormone-refractory prostate cancer was the one 
discovered in the LNCaP prostate cancer cell line (Veldscholte et al., 1992). The LNCaP 
cell line was originally established from lymph node metastases of a patient treated with 
hormonal therapy. In the cell line the mutation T877A in the ligand binding domain of the 
AR enables AR to be activated by other steroid hormones such as estradiol and 
progesterone, and even by antiandrogen flutamide, suggesting broadened ligand specificity 
(Culig et al., 1993). It has also been shown that AR point mutations occur spontaneously in 
transgenic adenocarcinomas of the prostate mouse model (TRAMP), and certain mutations 
are selected for by the changes (castration) in the androgen environment (Han et al., 2001). 
The mutated ARs from the flutamide-treated patients were also shown to be stimulated by 
flutamide. The most frequently found mutation among the flutamide-treated patients was 
identical to the mutation in the LNCaP (T877A). 
In addition to the missense mutations, it has been demonstrated that silent mutations in the 
AR gene may influence the mRNA stability or transcriptional regulation (Han et al., 2001).  
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2.5 Cross talk of AR with other signaling pathways 
 
It has been proposed that in the absence of a ligand, the AR activation could take place by 
cross-talk with various growth factors, protein kinase pathways. CaP progression is often 
associated with alteration of growth factor or growth factor receptor expression by the 
tumor (Russell et al., 1998) For example, it has been demonstrated that epidermal growth 
factor (EGF), epidermal growth factor receptor-2 (ERBB2/Her-2), keratinocyte growth 
factor (KGF/FGF-7), insulin-like growth factor-1 (IGF-1), protein kinase A (PKA), 
mitogen-activated protein kinase (MAPK), as well as IL-6 could activate the AR signaling 
(Culig et al., 1994, Abreu-Martin et al., 1999, Jenster et al., 2000, Craft et al., 1999, Sadar 
1999). An additional mechanism underlying ligand-dependent activation of the AR by 
these alternative pathways may involve phosphorylation of either the AR or its associated 
proteins (Sadar 1999, Ueda et al., 2002). 
It has been shown that the concentration of the IL-6 is elevated in the sera of the patients 
with metastatic and hormone-refractory prostate cancer (Drachenberg et al., 1999). An IL-
6 receptor is also expressed in a normal prostate and in CaP. The IL-6 has been shown to 
activate AR through the MAPK pathway interacting with the transcriptional coactivator 
p300 in the prostate cancer cells (Hobisch et al., 1998, Ueda et al., 2002, Debes et al., 
2002). It has thus been suggested that a network of protein kinase-coactivator-IL-6 is 
needed to induce the androgen-independent activation of the AR (Ueda et al., 2002). 
The IGF-1 signaling has been implicated in the progression to androgen-independence at 
least in LNCaP and LAPC-9 xenograft models, in which both the IGF-1 and its receptor 
IGF-1R are overexpressed (Nickerson et al., 2001). In addition, the inhibition of the IGF-
R1 has been shown to result in suppression of tumor growth and invasiveness in rat 
prostate cancer cells (Putz et al., 1999). 
Akt kinase is known to phosphorylate AR and enhances its transactivation potential even at 
low levels of androgens. Therefore stimuli that increase Akt activity, including Her2 may 
contribute to progression of CaP. The PI3K pathway is stimulated in LNCaP and PC-3 
cells by IL-6 and inhibition of IL-6 induced PI3K activity by wortmanin causes apoptosis 
in LNCaP cells (Chung et al., 2000) suggesting that this pathway can contribute to the 
survival and growth of CaP cells.  
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A recent article suggested forced overexpression of Akt kinase and Raf kinase in androgen-
dependently growing CaP cells led to transition to androgen-independent status (Gao et al., 
2006). 
 
2.6 AR coregulators in prostate cancer 
 
Fujimoto (2001) reported that the expression of the coactivator SRC1 was higher in 
refractory CaP. Gregory et al., (2001) found that the expression of both the SRC1 and TIF2 
was increased in hormone-refractory prostate cancer. The overexpression of these 
coactivators affected the ability of low-affinity ligands or minimal concentrations of the 
adrenal androgens to activate the AR in the castrated environment. Transactivation by AR 
was further increased by phosphorylation of the p160 coactivators suggesting a link to 
growth factor signaling pathways. Interestingly, it has also been shown that the ligand-
independent activation of the AR does not occur alone through the overexpression of the 
SRC1; it requires a functional MAPK pathway (Ueda et al., 2002). In the absence of the 
androgens, the protein-protein interaction of the SRC 1 and AR also seems to require IL-6 
(Ueda et al., 2002).  
The expression of the CBP has been detected in different prostate specimens, but no 
alterations in the level of expression have been reported (Comuzzi et al., 2003). It has also 
been shown that antagonist/agonist balance of antiandrogens flutamide and bicalutamide is 
influenced by the CBP. Indeed the expression of the CBP increased flutamide-induced AR 
activity up to 50% of the activation induced by the synthetic androgen R1881. 
Interestingly, recent work demonstrated that elevated level of corepressor SMRT in CaP 
cells lead to repression of target genes which are involved in antiproliferative action 
(Khanim et al., 2004). This suggests that enhanced corepressor expression is not always 
associated with growth inhibition, rather may promote the growth of CaP cells. 
 
2.7 Specific aim of the present study 
 
Androgen receptor (AR) mediates the biological effects of androgens and is implicated in 
the progression of the prostate cancer (CaP). AR functions by regulating the expression of 
target genes, either positively or in a negative manner. However, target gene regulation by 
other ligands, specifically antagonists has not been well addressed. Regulation of target 
genes often involves coregulatory proteins. This work attempts to address modulation of 
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target gene expression by corepressors and therapeutic ligand cyproterone acetate. As 
many signal transduction pathways are over expressed in CaP, it is possible that they boost 
the AR function in CaP cells; this possibility has been addressed in the following work. 
Corepressors repress anti-hormone bound AR function and bring the therapeutic advantage 
in CaP. It is therefore important to discover new AR corepressors with versatile action, 
especially those which can repress agonist-bound AR function. Mutants of AR found in 
CaP cells can be activated by many different non-cognate ligands for the reason that AR 
can use them as alternate agonists. The decreased corepressor to coactivator ratio observed 
in androgen-independently growing CaP cells also suggests the link between corepressors 
and inhibition of growth. Like many other regulatory proteins corepressor function is 
subject to regulation by post-translational modifications important being phosphorylation 
as well. Signal transduction pathways may enhance AR function possibly by functionally 
inactivating the corepressors molecules and this likelihood has also been addressed in the 
work undertaken. 
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3. Materials 
 
3.1 General instruments   Suppliers 
 
Agarose gel electrophoretic unit   Stratagene and Harnishmacher 
Analytical balance (s)   Sartorius 
Autoclave     Tecnomara/KSG 
Bacterial incubator    Stemmert 
Balance     Sartorius 
Blower     Rothenberger 
Cell cryo cooler    Nalgene 
Centrifuge     Heraeus biofuge 
CO2 incubator     NUNC 
Computer      Intel Pentium IV 
Cover slip     Mencel 
Deep freezer (-80 °C)    SEPATECH, Heraeus 
Dryer      Heraeus 
Freezer (-20 °C)     Liebherr 
Gel documentation system    Biometra 
Ice machine     Scotsman/Ziegra 
Incubator           Heraeus 
Incubator/Shaker    GFL 
Laminar hood     Heraeus, laminair 
Luminometer      SIRIUS Berthold Detection Systems 
Magnetic Stirrer    Janke & Kunkel 
Microliter pipettes     Gilson, Eppendorf 
Microscope      Axiovert 135, Zeiss 
Microwave     Privileg 
MilliQ machine    USF, Seral/ Mi 
Multipipette      Gilson 
Neubauer chamber    Assistent 
PH Meter      WTW pH96 
Pipetteboy     Braun/IBS Integra 
Quartz cuvette    Hellma 
Real time PCR machine   Roche, Corbett research 
Refrigerator (4 °C)     Liebherr, Foran 
Rocker     Bochem 
Shaker      Heidolph 
Sonifier      250 Branson 
Spectrophotometer     Eppendorf, Lab biochrom 
Thermal-Cycler     Eppendorf, PeqLab 
Timer      Roth 
UV-Trans-illuminator    Bachofer (366 nm), UVP (254nm) 
Vacuum pump    IBS Integra 
Vortex      Janke & Kunkel, Scientific instruments 
Washer     Newamatic 
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3.2 Consumables      
 
Cell culture dishes    Greiner, NUNC 
Cryovials     Nalgene 
Falcon 15 ml and 50 ml    Greiner, TPP 
Filter tips     Greiner 
Latex gloves     Braun 
Microfuge tube (1.5 ml and 2.0)   Eppendorf 
Nitrile gloves     Roth 
Paper towel     Kimberly Clark 
Parafilm      parafilm   
Pasteur pipette    Assistant 
PCR tubes      Biozym 
Petridishes      Greiner      
Plastic cuvette     Sarstedt 
Quick-SealsTM      Beckman 
Reagent bottles    Schott 
Sterile filter (0.2 μm, 0.8 μm)   Millipore, Schleicher & Schüll, Sartorius 
Tissue culture bottles     Greiner 
Tissue culture dishes    Greiner, NUNC 
 
3.3 Chemicals     
 
Acetic acid      Roth 
Active charcoal    Merck 
Adenosine tri-phosphate (ATP)   Roche 
Agar       Gibco, Invitrogen 
Agarose      Roth 
Ampicillin-Sodium salt    Merck, Serva 
Apo transferrin    Sigma 
Bacto tryptone    Applichem 
Biotin       Sigma 
Boric acid      Merck 
Bromophenol blue    Serva, Merck 
Calcium chloride    Roth 
Calf thymus DNA    Sigma 
Cesium chloride     Roth 
Chloramphenicol     Roth 
Chloroform      Merck 
Coenzyme A      PJK GmbH 
Di potassium hydrogen phosphate  Merck 
Di Sodium hydrogen phosphate   Merck 
Dimethylsulfoxide (DMSO)    Serva 
Dithiothreitol (DTT)     Sigma 
D-Luciferin     PJK GmbH 
DMEM cell culture media   Invitrogen 
dNTPs (dATP, dCTP, dGTP, dTTP)  MBI  
EDTA-sodium salt    Roth 
Ethanol      Roth 
Ethidium bromide solution (10 mg/ml)  Roth 
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F12 cell culture media   Sigma 
Fetal bovine serum (FBS)   Invitrogen 
Ficoll 400      Sigma 
Formaldehyde     Roth 
Glucose      Roth 
Glycerin      Roth 
Glycine      Roth 
HEPES (n-2-Hydroxyethylpiperazine)  Roth 
Hydrochloric acid    Roth 
Insulin      Sigma 
Isoamyl alcohol    Roth 
Isopropanol      Roth 
Lithium chloride    Merck 
Magnesium acetate    Merck 
Magnesium sulfate    Merck 
Manganese chloride    Merck 
Methanol      Merck 
Nonidet® P-40 (NP-40) substitute   Fluka 
Oligonucleotide    Eurogentec 
Penicillin/Streptomycin    Invitrogen 
Phenol      Roth 
Phenyl methyl sulfonyl fluoride (PMSF)  Sigma 
Potassium acetate    Merck 
Potassium chloride    Merck, Roth 
Potassium dihydrogen phosphate  Roth 
Protein-A-Sepharose     Amersham 
RPMI cell culture media   Invitrogen 
SDS ultrapure     Serva 
Sodium acetate    Roth 
Sodium chloride    Merck, Roth 
Sodium deoxycholate    Roth 
Sodium dihydrogen phosphate  Roth 
Sodium bicarbonate       Merck, Roth 
Sodium hydroxide pellets   Roth 
Sodium pyruvate    Invitrogen 
TRI®-Reagent      Peqlab 
Tris-Base      Roth 
Triton X-100      Sigma 
Trypsin      Gibco/Invitrogen 
Tween-20      Roth 
Xylene cyanol     Sigma 
Yeast extract      Difco, Oxoid 
β-Mercapto ethanol     Merck, Fluca 
3-(n-Morpholino) 
o-Nitrophenol-β-Galactopyranoside  Roche 
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3.4 Enzymes, hormones and Signaling inhibitors 
 
ENZYMES      
 
Alkaline Phosphatase (CIAP)   MBI  
Klenow Enzyme     MBI  
Lysozyme     Amersham, Serva 
Proteinase K      Sigma 
Restriction endonucleases    MBI Fermentas, Boehringer Mannheim 
Ribonuclease (RNase A)   Sigma 
Trypsin      Merck 
T4-DNA-Ligase     MBI  
T4-DNA-Polymerase     MBI  
Taq DNA Polymerase   Invitrogen     
 
HORMONES     
 
Casodex (Cas)     Zeneca 
Cyproterone acetate (CPA)    Sigma 
Dihydrotestosterone     Sigma 
Geneticin (G-418)     Invitrogen 
Hydroxy flutamide (OH-F)    LKT Laboratories Inc, Schering AG 
Hygromycin     Sigma 
Methyltrienolone (R1881)    Perkin Elmer 
Tri-iodo thyronine (T3)   Sigma 
 
INHIBITORS     
 
AG1517      Alexis  
HA1077     Calbiochem 
PP2       Calbiochem 
U0126      Calbiochem 
LY294002     Calbiochem 
 
 
3.5 Commercial kits and ready-to-use materials    
 
 
Complete Mini, Protease inhibitor  Roche (Cat # 11 836 152 001) 
DOTAP transfection reagent   Carl Roth (L787.3) 
Maxiprep, midiprep kit   Marligen (11452-026 and 11451-028) 
QIAquick PCR purification Kit   Qiagen (28104) 
PCR taq Polymerase Kit    Invitrogen (18038-042) 
Salmon Sperm DNA/Protein-A-Agarose  Upstate (Cat # 16157) 
SuperscriptTM One-Step RT-PCR   Invitrogen (12574-030) 
 
 
3.6 Antibodies employed in ChIP  
    
 
α-AR (PG21)     Upstate (4 µl per IP) 
MATERIALS 
 
20
α-SMRT (PA1-842)    Alexis (4 µl per IP) 
α-Alien (PepAK2)    Rabbit polyclonal (home-made, 4 µl per IP) 
α-c-myc (9E10, sc-40)   Santa Cruz (5 µl per IP)  
α-IgG Rabbit (sc-2027)   Santa Cruz (2 µl per IP)    
Goat α-Rabbit IgG (sc-3836)   Santa Cruz (2 µl per IP) 
 
 
3.7 Oligonucleotides 
 
Sequencing Oligos 
 
Gal94-Primer:   5‘-CCT CGA GAA GAC CTT GAC CTT GAC ATG-3‘ 
 
T7:     5’TAA TAC GAC TCA CTA TAG GG-3´  
 
AR-sense:    5´CAG GAA AGC GAC TTC ACC-3´  
 
rev. primer:   5´AGG CGA TTA AGT TGG GTA3´ 
 
AR-67:   5´TTC CAG AAT CTG TTC CAG AGC3´ 
 
 
Oligos employed in ChIP 
 
PSA ARE I sense:   5´TCT GCC TTT GTC CCC TAG AT3´ 
 
PSA ARE I antisense. 5´AAC CTT CAT TCC CCA GGA CT3´ 
 
PSA ARE III sense:   5´GAG GTT CAT GTT CAC ATT AGT ACA C3´ 
 
PSA ARE III antisense:  5´ATT CTG GGTT TGG CAG TGG AGT GC3´ 
 
-2.0 kb PSA sense:  5’AGC ATC AGC CTT ATC TCC A3’ 
 
-2.0 PSA antisense:  5’ACT CCA ATC TGA TCC TCC A3’ 
 
-7.5 kb PSA sense:  5’AGT GAT TCT CCT GCC TCA3’  
 
-7.5 kb PSA antisense: 5’AGC ATG TAG GCT CTG GAA3’ 
 
PSCA enhancer sense: 5’GAA CTT TCC CTC TGG ACA C3’ 
 
PSCA enhancer antisense:  5’GTG AGG TCA GAA CCC AAC3’ 
 
-2.0 kb PSCA sense:  5’TAC CCA GGG CCA TAT CTC3’ 
 
-2.0 kb PSCA antisense: 5’GAC CAA GGC TTT ATC ATC AG3’ 
 
Maspin promoter sense: 5’CGG CAC TCC TCT CCT AC3’ 
 
Maspin promoter antisense: 5’TCA ACC TCC CCA AAT GC3’ 
MATERIALS 
 
21
 
-2.0 kb maspin sense:  5’TAC TTG GGA GGC TGA GAC3’ 
-2.0 kb maspin antisense: 5’GAT CAG GCT TCT AAA GAG AC3’ 
 
Real time PCR primers 
 
PSA sense:    5´ACT GCA TCA GGA ACA AAA GCG TGA3´ 
 
PSA antisense:   5´CGC ACA CAC GTC ATT GGA AAT AAC3´ 
 
PSCA sense:   5´TGC AGG TGGAGA ACT GCA3´ 
 
PSCA antisense:  5´TCT GTG AGG AGT GGC ACA3´ 
 
Maspin sense:   5´GCT AAA GGT GAC ACT GCA A3´ 
 
Maspin antisense:  5´TTT GGT CTG GTCGTT CAC A3´ 
 
GAPDH sense:   5´CGG AGT CAA CGG ATT TGG TCG TAT3´ 
 
GAPDH antisense:    5´AGC CTT CTC CAT GGT GGT GAA GAC3´ 
 
β-Actin sense:   5´ACA GAG CCT CGC CTT TGC CGA3´ 
 
β-Actin antisense:  5´CAC GAT GGA GGG GAA GAC G3´ 
 
 
3.8 DNA standard markers 
 
 
λ DNA EcoRI/HindIII (MBI)     pUC19 DNA MspI (MBI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Size (bp) 
21227 
5148 
4973 
4268 
3530 
2027 
1904 
1584 
1375 
947 
831 
564 
Size (bp) 
501 
489 
404 
331 
242 
190 
147 
111 
110 
67 
34 
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3.9 Bacterial strains and Eukaryotic cell lines 
 
Bacterial strains 
 
Escherichia coli DH 5α (Described by Hanahan, 1983) 
 
Genotype of the strain  F’/endA1 hsdR17 (rK--mK+) supE44 thi-1 recA1 gyrA 
(Nalr) relA1 Δ(lacZYA-argF)U169 (ϕ80lacZΔM15). 
 
 
Escherichia coli HB101 (Described by Boyer and Roulland-Dussoix, 1969) 
 
Genotype of the strain  F-(gpt-proA) 62 leuB6 supE44 ara-14 galK2 lacY1 
Δ(mcrC-mrr) rpsL20 (Strr) xyl-5 mtl-1 recA13. 
 
 
Cell Lines 
 
 
CV1 (ATCC CCL-70) 
 
This cell line was raised from the kidney epithelial cells of African green monkey 
(Ceropithecus aethiopis). The cells grow in an anchorage-dependent manner forming 
monolayer, show contact inhibition, and exhibit morphology similar to fibroblasts. They 
were grown in DMEM containing 10% FBS, 1% pen/strep solution and 1 mM HEPES pH 
7.5 in the humidified incubator at 5% CO2.  Their utility in NHR research lies in the fact 
that they lack in endogenous NHR expression, ideal to find out the functions of not only 
ectopically expressed AR.  
 
 
LNCaP (ATCC CRL1740) 
 
The cell line was derived from a lymph node metastasis biopsy conducted on a CaP 
patient. They grow in an androgen-dependent manner and express endogenous mutant 
form of AR.  Cells do not show contact inhibition, and therefore tend to form foci. Cells 
are grown in RPMI (Roswell Park Memorial Institute) media containing 10% FBS, 1% 
pen/strep., 1% Sodium pyruvate solution and 1 mM HEPES pH 7.5 in the humidified 
incubator at 5% CO2  (Procured from Dr. J. Klug, Giessen).  
 
 
C4-2 
 
This cell line was derived from parent cell line LNCaP after their painstaking long-term  
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culture without androgens and therefore they show an androgen-independent phenotype. 
They grow faster than the parent cell line and do not show growth inhibition by antagonist 
Cas. They do not show contact inhibition and can form foci. These cells require a growth 
factor enriched media called “T-media” which is modified from DMEM and contains in 
addition 10% FBS, 20% F-12 media, 5 μg/ml insulin, 13.6 pg/ml T3, 5 μg/ml 
apotransferrin, 0.25 μg/ml biotin, 25 μg/ml adenine and 1% pen/strep, 1 mM HEPES pH 
7.5. Cells are grown at 37 °C in the humidified incubator at 5% CO2.  (Cells were kindly 
by Dr. G. Thalmann, Switzerland) 
 
PC3-wt AR 
 
PC3-wt AR cells were derived from PC3 CaP cells. Unlike PC3 cells, these cells express 
functional AR which has been stably integrated. They are grown in DMEM (Dulbecco’s 
Modified Eagle’s Media) containing 10% FBS, 1% pen/strep solution and 1 mM HEPES 
pH 7.5 in the humidified incubator at 5% CO2. (Procured from Andrew Cato) 
 
3.10 Plasmids 
 
The following plasmids were used for the work undertaken 
 
 
Name of the plasmid    Source/Reference 
 
 
Reporter plasmids 
 
1. pARR3-Luc      R. J. Matusik, Nashville, TN 
2. pCMV-LacZ      U. Deutsch, Bad Nauheim 
3. pMMTV-Luc      Gast et al., 1998 
4. pPSA-Luc       Cleutjens et al., 1997 
5. p(UAS)4-TATA-Luc    Frauke Goeman, AG Baniahmad 
6. pPSCA-2.7-3.0     Robert Reiter, US 
7. pPSCA-TATA     Robert Reiter, US 
 
Control Plasmids 
 
1. pSG5                 Stratagene 
2. pcDNA3       Invitrogen 
3. pABΔgal       Baniahmad et al., (1990) 
4. pCMX-VP16     Ronald Evans 
 
 
 
 
MATERIALS 
 
24
Eukaryotic expression plasmids 
 
1. pSG5-AR       Gast et al., 1998 
2. pSG5-hAR-T877A     M. Asim, AG Baniahmad 
3. pSG5-hAR-K385R/K518R    M. Asim, AG Baniahmad 
4. pVP16-cSMRT      K. Busch, M. Muller 
5. pVP16-cLCoR     M. Patz, AG Baniahmad 
6. pSG5-LCoR     John White, Canada 
7. pSG5-LCoR-mut     John White, Canada 
8. pCMX-VP16-Alienα    Udo Moehren, AG Baniahamd 
9. pABgal94-LCoR     M. Asim, AG Baniahmad 
10. pCS2+MT      M. Schulz (Rupp et al., 1994)  
11. pCS2+MT-LCoR     M. Asim, AG Baniahmad 
12. pAB-VP-ARDBD    M. Asim, AG Baniahmad 
13. p5HB-AR-K385E/K518E   J.A. Iniguez-Lluhi 
14. pABΔgal-Trip15/Alien     U. Dressel, AG Baniahmad  
15. pSG5-AR-ΔHBD     H. Dotzlaw, AG Baniahmad  
16. pSG5-AR-ΔΝΤ      Dotzlaw et al., 2002 
17. pSG5-AR-Δ39−171     Dotzlaw et al., 2002 
18. pSG5-AR-Δ39−328     Dotzlaw et al., 2002 
19. pSG5-AR-Δ1−171     Dotzlaw et al., 2002 
20. pSG5-AR-Δ1−328     Dotzlaw et al., 2002 
21. pSG5-AR-1-328      Dotzlaw et al., 2002 
22. pSG5-AR-1-505      Dotzlaw et al., 2002 
18. pETE-Hyg     Protopopov, 2002 
19. pABgal94-Alien     Dressel et al., 1999 
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4 Methods 
 
4.1 Working with DNA 
 
Storage 
 
 
All experiments were carried out in sterile environment. Solutions were prepared using 
double distilled milli Q water as stocks. Solutions were further diluted according to the 
requirement by making working dilutions. It is recommended to store all Plasmid DNA at 
–20 °C in TE buffer (Ausubel et al., 1989). The DNA was dissolved in either TE buffer or 
preferably in ddH2O.  
 
 
 
 
 
  
 
 
4.1.1 Minipreparation of plasmid DNA 
 
TELT method 
 
TELT method was first described by Holmes and Quigley in 1981. Modified by Wilmzig 
in 1985. The advantage of this method lies in the instant recovery of the plasmid DNA. 
This method is particularly useful in analytical preparation of the plasmid DNA e.g., for 
purpose of restriction digestion etc. in generation of plasmid vectors.  
 
 
 
 
 
 
 
In this method, 1.5 ml of overnight LB-grown bacterial culture was used for the isolation 
of plasmid DNA. Culture was transferred to a 1.5 ml reaction tube and centrifuged for 3 
minutes at 4000 rpm, in Hettich microlitre lab centrifuge. The supernatant was vacuum 
discarded and the pellet was resuspended in 200 μl of TELT buffer by vortexing and 20 μl 
TE Buffer  
Tris-HCl (PH 7.5)  10 mM  
EDTA (PH 8.0)           1 mM  
Filter sterilised 
LB Medium  
Bacto tryptone  10 g/l  
Yeast Extract   5 g/l  
NaCl    5 g/l  
Autoclaved 
TELT Buffer  
Tris-HCl (PH 7.5)  50 mM  
EDTA   62.5 mM  
Triton X-100   0.4 % (v/v)  
LiCl    2.5 M 
Stored at 4 °C. 
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of lysozyme solution (10 mg/ml in ddH2O). The probes were quickly incubated at 100 °C 
for 1 min for cell lysis, making solution viscous. Probes were taken out and vigorously 
shaken manually and then incubated on ice for 10 min. Then probes were centrifuged at 
13.000 for 10 min and the pellet was discarded. Supernatant was added with 2 volumes of 
absolute ethanol and the probes were vortexed followed by incubation at RT for 15 min to 
precipitate DNA. Again, the probes were centrifuged at 13.000 rpm for 20 min Supernatant 
was vacuum discarded and the plasmid DNA pellet was twice washed with 1 vol. of 70% 
ethanol. Ethanol free DNA pellet was dissolved in 30 μl of TE buffer and left at RT for at 
least 45 min.  
In order to carry out restriction analysis, 5 μl of this DNA solution is sufficient. This 
method is fast but leaves at the end much RNA intact forming smear on gel. Thus, to avoid 
RNA smear, probes should be mix with gel loading buffer containing RNase A 
(concentration 0.5 mg/ml) for 10 min before loading to the gel. This remains the method of 
choice for HB101 strain of E. coli. 
 
 
Alkaline Lysis method  
 
Devised by Birnboim and Doly (1979) this method of plasmid DNA extraction was started 
with 1.5 ml of overnight grown bacterial culture in LB under selective antibiotics. Cells 
were pelleted by centrifuging the culture at 13000 rpm for 1 min in Hettlich table top 
centrifuge.  
 
 
 
 
 
 
 
 
 
 
 
 
The cell pellet was resuspended by vortexing in 100 μl of sol I. This was followed by 
incubation with 200 μl of sol II at RT, followed by immediately inverting the 1.5 ml 
reaction tube 3 times to uniformly mix the solution. This solution, not only lyses the cells 
but leaves genomic DNA entangled in a dense mass which can later on be removed by 
centrifugation, leaving plasmid DNA in solution. The lysis reaction was then stopped by 
Sol I  
Tris-HCl (PH 8.0)  25 mM 
EDTA   10 mM  
Glucose   50 mM  
Autoclaved, refrigerated 
Sol II  
NaOH   200 mM  
SDS   1 % (w/v)  
Fresh prepared 
Sol III  
CH3COOK 3 M  
CH3COOH  115 ml/l 
Refrigerated 
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adding 150 μl of sol III, and after vortexing, the probes were kept at -20 °C for 5 min and 
were again spun at 13.000 rpm for 5 min to sediment the heavier mass of genome DNA 
and residual proteins. The supernatant was again transferred to a fresh 1.5 ml reaction tube 
and spun once more at 13.000 rpm for 5 min and again transferred into a fresh 1.5 ml 
reaction tube. Plasmid DNA was precipitated by adding 1 ml of absolute ethanol and 
vortexing briefly. The probes were incubated at RT for 5 min and centrifuged at 13.000 
rpm for 5 min Supernatant was discarded and plasmid DNA was washed with 70% ethanol. 
The probes were again centrifuged at 13.000 rpm, and air-dried for a short time after 
discarding the supernatant; the probes were dissolved in 30 μl of TE buffer. 
 
 
4.1.2 Maxipreparation of plasmid DNA 
 
CsCl method 
 
This method, modification of alkaline lysis method described by Holmes and Quigley 
(1981), is particularly useful for making large amount of ultra pure plasmid DNA (1-10 
mg) free of genomic DNA as well as RNA. Use of CsCl gets rid of RNA impurities by 
creating a density gradient (Radloff et al., 1967). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To start with 3 ml of overnight LB grown bacterial “pre culture” was added to the 400 ml 
of TB (360 ml TB media + 40 ml phosphate buffer) media containing appropriate 
antibiotics. The culture was grown for 8-9 hrs in the incubator shaker at 37 °C with 
vigorous shaking after which, growth of the bacteria was stopped by adding 2 ml of 
Sol I   
Tris-HCl (PH 8.0)  25 mM 
EDTA   10 mM  
Glucose   50 mM  
Autoclaved 
Added 4 mg/ml lysozyme just 
before use 
Sol II  
NaOH   200 mM  
SDS   1 % (w/v)  
Fresh prepared 
Sol III  
CH3COOK 3 M  
CH3COOH  115 ml/l 
TB Medium   
Bacto tryptone  12 g/l    
Yeast Extract  24 g/l    
Glycerine  4 ml/l  
Autoclaved   
10x Phosphate Buffer  
KH2PO4 170 mM  
K2HPO4 720 mM  
Autoclaved  
1/10 vol to  be added to TB media 
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chloramphenicol (34 mg/ml in ethanol), which arrests the bacterial growth by stopping 
synthesis of new proteins so the energy can more efficiently be used for the amplification 
of plasmid DNA and therefore, this step is often referred as “plasmid amplification”. 
Overnight incubation with chloramphenicol was followed by the harvesting of bacterial 
culture by centrifuging at 4000 rpm for 10 min at 4 °C (Beckmann JA10 rotor). The pellet 
was resuspended in 10 ml of sol I containing 4 mg/ml lysozyme avoiding bubbles to make 
a homogenous paste and then allowed to stand at RT for 5 min Lysis follows by the 
addition of 20 ml of freshly prepared sol II and then inverting the tube 5 times and let it 
incubated on ice for 10 min That caused cell lysis and the reaction was then stopped by 
adding 15 ml of sol III which was mixed well by inverting and kept on ice for 10 min. The 
probes were centrifuged for 15 min at 6000 rpm at 4 °C (Beckmann JA10.  The supernatant 
from each probe was divided into 2 falcons of 50 ml each by filtering through muslin cloth 
to avoid impurities. Now the DNA was precipitated by adding 0.6 volume of isopropanol 
which selectively precipitates DNA, mixed by vortexing and centrifuged at 5800 rpm for 
15 min at RT (Heraeus minicentrifuge). The DNA pellet obtained was dissolved in 1.5 ml 
of TE buffer in water bath at 37 °C. After proper dissolution the samples were re united 
and 4.5 gms of CsCl was added and then dissolved by again keeping in water bath at 37 
°C. To each sample, 0.5 ml of ethidium bromide (10 mg/ml) solution was added followed 
by centrifugation for 10 min, 6000 rpm at RT in Heraeus centrifuged. The supernatant was 
then collected in Beckman-Quick-Seal TM ultracentrifuge tube was filled to the graduated 
point using 50% w/v of CsCl solution. The properly weighed tubes were sealed by the 
thermal sealer and were centrifuged at 55.000 rpm overnight at 20 °C using Beckman 
XL70 ultracentrifuge with rotor VTi 90. The upper plasmid DNA band, and lower RNA 
band and the impurities on the wall of the tube were visible. The tube was carefully 
punctured from the side wall using a needle and the plasmid DNA band was collected with 
a syringe slowly to avoid nicks in the DNA. The DNA band was transferred to a new 
Quick seal tube which was filled with 50% w/v CsCl.  After proper sealing the tubes were 
again centrifuged at 70.000 rpm for 3 1/2 hrs at 20 °C to remove EtBr. Plasmid DNA was 
taken in a fresh 15 ml falcon and 2 ml of CsCl-saturated isopropanol was vortex-mixed. 
Out of two visible phases, the upper red phase containing EtBr was discarded, and to the 
lower phase with plasmid DNA, 2 ml CsCl-saturated isopropanol was mixed and discarded 
unless the lower phase becomes completely colorless. This step was repeated once again 
for 2 more times to remove any traces of EtBr left. To the plasmid DNA added 2 volumes 
of milli Q water followed by addition 0.6 volume of isopropanol, mixed well and incubated 
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at RT for 10-15 min It was centrifuged for 20 min, RT, 6000 rpm, Heraeus minifuge a 4 
°C. The pellet was washed with 5 ml 70% EtOH and dried. Finally, the DNA dissolved in 
500-700 µl of TE or milli Q water depending on the rough yield. 
 
Maxiprep protocol (Marligen kit-modified) 
 
A typical yield of 1-4 mg DNA is desired. The culture was started as 3 ml overnight grown  
preculture to inoculate 400 ml LB media containing suitable antibiotic in appropriate 
concentration and grown overnight. Cells were centrifuged at 4000 rpm for 10 min at 4 °C  
the supernatant was discarded and cells were homogenized in 10 ml of solution E1 
followed by lysed with 10 ml of E2 at RT for 5 min E2 must be gently mixed by inverting 
the tube 5 times. 10 ml of neutralization buffer E3 was added to avoid excessive lysis by 
inverting the tube 5 times. The lysate was centrifuged and the supernatant containing the 
plasmid DNA was loaded sieving through muslin cloth on the affinity column which was 
pre equilibrated using 10 ml of E4 equilibration buffer. The column was washed once with 
60 ml wash buffer E5 to remove the impurities. The DNA was finally eluted in 15 ml of 
elution buffer E6. To the eluted solution 10.5 ml of isopropanol was added, mixed by brief 
vortexing and centrifuged at 4000 rpm for 30 min at 4 °C. The DNA pellet obtained was 
washed with 5 ml of 70% ethanol and centrifuged again at 4000 rpm for 5 min at 4 °C. The 
pellet obtained was air-dried and subsequently dissolved in appropriate volume of ddH2O.  
 
4.1.3 Midiprep protocol (Marligen-kit modified) 
 
The midiprep is usually carried out when only moderate amounts (1-2 µg) of highly pure 
DNA is required as for sequencing etc.  
The culture was started with 3 ml overnight grown preculture to inoculate 100 ml LB 
media containing suitable antibiotic in appropriate concentration and grown overnight. 
Cells were centrifuged at 4000 rpm for 10 min at 4 °C. Supernatant was discarded and cells 
were homogenized in 4 ml of solution E1 followed by lysis with 4 ml of E2 and gently 
mixed at RT for 5 min 4 ml of neutralization buffer E3 was then gently mixed. The lysate 
was centrifuged and the supernatant containing the plasmid DNA was filtered through 
muslin cloth on the affinity column which has been pre equilibrated using 10 ml of E4 
equilibration buffer. The column was washed twice with 10 ml wash buffer E5 to remove 
impurities. The DNA was finally eluted in 5 ml of elution buffer E6. To the eluted solution 
containing DNA, 3.5 ml of isopropanol was added, mixed by brief vortexing and 
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centrifuged at 4000 rpm for 30 min at 4 °C. The DNA pellet obtained was washed with 3 
ml of 70% ethanol and centrifuged again at 4000 rpm for 5 min at 4 °C. The pellet obtained 
was air-dried and subsequently dissolved in appropriate volume of ddH2O. A typical yield 
of 100-200 μg DNA was achievable. 
 
4.1.4 Determination of DNA concentration 
 
 
Each DNA molecule contains conjugated double bonds in sugar atoms which allows the 
absorption of ultra-violet spectrum of light and forms therefore the basis for the 
spectrophotometric determination of DNA concentrated (Ausubel et al., 1989). Briefly, the 
DNA was diluted in TE, and measured spectrophotometrically at wave-lengths of 260 nm 
and 280 nm. The following formula was employed for determining the concentration. 
 
 
 
 
 
 
 
Abs. constant for dsDNA is 50, for ssDNA which absorbs more light compared to same 
quantity of dsDNA this value is 40. The purity of the DNA sample can be checked by the 
ratio of abs. values at 260/280 nm. For pure DNA sample the value should stand 1.8. 
Values less than 1.8 indicate the contamination by proteins. 
 
4.1.5 Gel electrophoresis of DNA 
 
A sea weed product, agarose is a natural carbohydrate polymer which forms a matrix and 
frequently used to resolve the negatively charged DNA fragments under the electric field 
based on their size (Southern, 1979) with the smaller fragments running faster than the 
bigger ones. The degree of resolution depends on the size of the lattice formed by the 
agarose upon solidification. High concentration agarose forms smaller pores and are 
therefore resolving fragments with very little difference in size, however low percentage 
(w/v) of agarose that forms lattice with bigger pores and useful for resolving fragments 
with significant difference in size. There are two kinds of gels which have here been used. 
 
 
 
Concentration of dsDNA = OD260 x dilution factor x 50 = in µg/ml 
 
Purity of DNA = OD260/OD280   >   1.8 
METHODS 
 
31
Analytical agarose gel 
 
Agarose gels with varying percentage of agarose were prepared with 0.8-1.5% of agarose 
(Johnson and Grossman, 1977; Southern, 1979). The required quantity of agarose powder 
was dissolved in the 0.5x TBE containing 0.2 μg/ml EtBr, by boiling in a microwave oven. 
Once cooled to 55 °C the solution was poured in a gel chamber containing appropriate size 
combs for casting the wells for loading the DNA samples.  
 
 
 
 
 
 
 
 
 
 
 
The DNA to be tested in gel was dissolved in water or TE. To the appropriate DNA 
volume, 10x gel loading dye was mixed and was loaded in the well along with 0.5 μg DNA 
standard markers to be run parallely. The electric field of 10 volts/cm was applied to 
separate the fragments obtained by restriction digestion of a plasmid DNA (for fragments 
>2kBp 5V/cm). After completion of the run the fragments of the DNA were visualized on 
the UV trans-illuminator (254 nm) and photographed by Polaroid camera or digital gel 
documentation system. 
 
Preparatory agarose gel 
 
 
 
 
 
The gel electrophoresis with aim to obtain DNA for further experimentation, especially 
cloning fragments was carried out in gels made out of another derivative of agarose having 
low melting point (LMP agarose). For that purpose generally 1% LMP agarose gels are 
10x TBE Stock 
Tris-HCL (PH 8.3)  0.9 M  
Boric Acid   0.9 M  
EDTA   20 mM 
10x Gel Loading Dye 
Ficoll 400           40 %(w/v)  
Bromophenol blue  0.05 %(w/v)  
Xylene cyanol 0.05 %(w/v)
Ethidium bromide (EtBr)  
Stock Solution 
EtBr  10 mg/ml in ddH2O  
50x TAE  
Tris   2 M  
EDTA          0.5 M  
PH adjusted to 7.7 with acetic 
acid 
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common in use. The LMP agarose was dissolved in 1x TAE buffer (containing 0.5 μg/ml 
EtBr) to form a gel (Blin et al., 1975) and fragments were separated for ligation. The 
electrophoresis was carried out at 4 °C with 4 volts/cm potential difference. After 1 hr 
running the gel was visualized on a UV trans-illuminator with 365 nm wavelength. The 
fragment was cut out of the gel, weighed and diluted with 4 volumes of ddH2O. For 
dissolution the probe was incubated in water bath at 65 °C for 10 min with mixing in 
between at RT and was stored for future use at -20 °C. 
 
4.1.6 Cleavage of DNA using restriction enzymes 
 
 
Restriction enzymes isolated from prokaryotes have become molecular scissors for routine 
research in molecular biology. Type II restriction enzymes, also called restriction 
endonucleases are the most common among them. They recognize a specific sequence in 
the DNA which is most often a palindrome, and break the phosphodiester bond, linking 
two nucleotide entities together. Depending on the exact site of cleavage they either 
generate overhangs which being sticky in nature with affinity towards the complementary 
sequence therefore preferred in cloning. Blunt ends, however are generated when the 
enzyme cut on both strands at the same site (Ausubel et al., 1989). 
The enzyme activity is shown in units (U), with 1U representing the amount required to 
digest 1 μg of λ-DNA in 1 hr at 37 °C. Generally for analytical digestion of DNA 1 U 
suffices for 5 μl of miniprep DNA or 1 μg of DNA, however, when the purpose is clone a 
restriction fragment use of more units can be recommended in order to restrict every single 
plasmid molecule, which otherwise will hinder the selection of the right clone afterwards.  
 
4.1.7 Dephosphorylation of DNA ends 
 
The restriction fragment to be subcloned into a vector contains a 5´ phosphate group 
generated as a result of restriction acts as a substrate for ligation also with its own 3´ 
hydroxyl group, which may severely decrease the efficiency of ligation. Therefore, in order 
to prevent the self intra-molecular ligation the 5´ phosphate group was enzymatically 
removed by incubating the DNA fragment with 5 U of calf intestinal alkaline phosphatase 
(CIAP) at 37 °C for 30 minutes. This decreases the probability of intra molecular ligation 
and enhances the occurrence of intermolecular ligation between fragment to be cloned and 
the vector. 
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4.1.8 Filling of 5´ recessive termini and trimming of 3´ overhangs 
 
In order to generate compatible ends for ligation, the protruding ends at the 5´ were filled 
by Klenow fragment to generate blunt ends. Klenow uses the 3´ OH group as primer and 
extends it 5´→3´direection adding nucleotides complementary to the opposite strand 
(Tabor and Richardson, 1987). This reaction uses dNTPs (dATP, dCTP, dGTP, dTTP; 5 
mM solution) as substrate and requires incubation at 37 °C for 30 min. Another situation 
which prerequisites the presence of blunt end at a 3´ overhang site involves the trimming of 
protruding ss nucleotides by 3`→5` exonuclease activity of T4-DNA polymerase. 
 
 
4.1.9 Ligation  
 
 
 
 
 
 
 
 
 
To carry out sticky-sticky ends ligation between two DNA molecules, a vector to insert 
ration 1:2 to 1:3 was used however, for blunt-blunt end ligation a higher vector to insert 
ration should be used. e.g., 1:4-1:5. The ligation was carried out in a total reaction volume 
of 30 μl with 3 μl T4-DNA ligase buffer and 3 to 10 units of the ligase depending on the 
ends of the DNA. Mixture was kept overnight in dark at RT for overnight. Later on 15 μl 
of the reaction mixture was used to transform competent E. coli cells. 
 
4.1.10 The Polymerase Chain Reaction 
 
 
The method to amplify a DNA fragment or molecule became automated with the discovery 
of the bacteria Thermus aquaticus which grows in the hot springs of the Yellowstone 
national park in the US. To amplify the given fragment of DNA, PCR is almost always in 
vitro method of choice. It utilizes two spanning primers for the exponential increase in the 
DNA amount. The key to the reaction is a thermo stable DNA polymerase which can carry 
out many cycles of addition of nucleotide to the existing DNA strand at elevated 
temperatures without being inactivated.  
10x Ligase Buffer  
Tris-HCl PH 7.8  400 mM  
MgCl2   100 mM  
DTT    100 mM  
ATP        5 mM 
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PCR is also used to quantify the amount of DNA precipitated by an antibody directed to a 
DNA binding protein and hence indicates the strength of in vivo recruitment of a protein in 
question on the DNA fragment amplified. 
 
 
 
 
 
 
 
 
 
In order to avoid pipetting errors a master mix containing the above-mentioned 
components and DNA was prepared and individually added to each of the sample.  
PCR employing thermal cycler involves repeated cycles of denaturation, annealing and 
extension which were programmed as shown below 
 
 
 
 
 
 
 
 
 
 
 
 
It is noted that the PCR was carried out in “Hot start” mode by initially denaturing the 
DNA at 94 °C for 3 min. The primary advantage of hot start PCR is that the product 
obtained are of high specificity as a result of precise annealing of the primers at correct 
locations. Therefore it avoids amplification of any non-specific DNA fragment. 
 
 
 
 
Component  Volume [μl]   Final Concentration 
10 x Buffer   3.5    1x 
10 mM dNTPs  0.7    0.2 mM each 
50 mM MgCl2  1.050    1.5 mM 
100 mM Fwd primer 0.175    0.5 μM 
100 mM Rev. primer 0.175    0.5 μM 
Taq-Pol (5 U/μl)  0.175     
H2O    24.225 
DNA    5.00 
   Σ 35.000  
Initial denaturation   94 °C (hot start PCR) 
Denaturation    94 °C for 45 sec. 
Annealing    depending on the Tm of primer 
    (Generally chosen Tm + 5 to 10  °C) 
Extension   72 °C, Approx. 90 sec.  
(depending on length of DNA) 
Final extension  72 °C for 10 min 
Cooling    4 °C
30 to 
39 
cycles 
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4.2 Working with RNA 
 
Working with RNA is more demanding than working with DNA, because of the chemical 
instability of the RNA and the ubiquitous presence of RNases: Unlike DNases, RNases do 
not need metal ion co-factors and can maintain activity even after prolonged boiling or 
autoclaving. Therefore special precautions were taken when working with RNA. It is 
therefore recommended to allocate a special area for RNA work only. 
 
4.2.1 Storage of RNA 
 
RNA was aliquoted in ethanol or isopropanol and stored at -70 °C. Most RNA molecules 
are relatively stable at this temperature. Ethanol or isopropanol were discarded by 
centrifugation and the RNA pellet was resuspended in appropriate amounts of RNase-free 
water. As for DNA, RNA sample should always be kept on ice when preparing an 
experiment. 
 
4.2.2 Extraction of RNA from eukaryotic cells 
 
The extraction was carried out by the modified method from Chomczynski and Sacchi 
(1987) for the isolation of highly pure RNA from the eukaryotic cells. Cells were washed 
first with PBS. 1 ml of Trifast® reagent (a metaphasic solution of phenol and guanidium iso 
thio cyanate) was added to each of the six well on cell culture plate. The cells were gently 
resuspended 5-6 times with blue microtip after which it was incubated for 5 min at RT. 0.2 
ml of chloroform was then added and the samples were shaken vigorously by hand for 15 
sec followed by RT incubation for 3-10 min the samples were centrifuged at 12.000 rpm 
for 5 min Out of two phases formed, upper aqueous phase was taken into a fresh 1.5 ml 
reaction tube and vortex-mixed with 0.5 ml isopropanol. Samples were incubated on ice for 
10-15 min and centrifuged at 12.000 rpm for 30 min the supernatant was discarded and the 
pellet was washed with 1 ml of 75% ethanol by vortexing and centrifugation for 8 min at 4 
°C. The pellet was air-dried for 20 sec by letting the lid open and then dissolved in 
appropriate amounts of RNase free water and the concentration of RNA was measured by 
nanodrop® instrument. Alternatively concentration measurement was done by conventional 
UV-Vis spectrophotometer with the abs. constant 40 for RNA. 
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4.2.3 cDNA synthesis and Real-Time PCR 
 
The RNA pellet obtained from a single well of the six well plate, was dissolved in ~25 μl 
of water. 2 µg RNA was dissolved in final 8 μl volume of water and mixed with 4 μl of  
 
 
 
 
 
primer mix (2 μl oligo + 2 μl random) and kept at 70 °C for 15 min before leaving on ice 
for 1 min followed by addition of 7 μl master mix with gentle mixing and brief 
centrifugation. Further, incubation first at 25 °C for 10 min and 42 °C for 2 min was 
completed. To the reaction mixture 1 μl of Superscript II was added and again incubated at 
42 °C for 55 min and later cooled to 4 °C. The prepared cDNA was stored at -20 °C. To 
carry out real time PCR, 8 μl of SYBR green (Invitrogen) was taken in light cycler 
capillaries and 2 μl of the cDNA was added. The capillaries were covered and briefly 
centrifuged to bring the liquid to bottom. These capillaries were then transferred to light 
cycler for real time transcript analysis. 
 
4.3 Working with Bacteria 
 
4.3.1 Bacterial transformation 
 
Transformation of HB101/DH5α Strains 
50-100 μl (depending on degree of competence) competent cells were thawn on ice. 0.5 μg 
of plasmid DNA was carefully mixed by very gentle pipetting. DNA and cells were 
Incubated on ice for 30 min Heat shock was given at 37 °C water bath for 2 min followed 
by addition of 1 ml cold LB and cells were incubated at 37 °C for an hr and centrifuged at 
3000 rpm for 5 min 1 ml of the supernatant was discarded and rest plated on amp-agar 
plate and incubated at 37 °C incubator overnight. Bacterial colonies were observed 16 hrs 
later. 
Conc. of RNA = OD260 x dilution factor x 40 = µg/ml 
Mastermix 
First strand buffer 4 μl 
DTT, 0.1 M  2 μl 
dNTP 10 mM  1 μl 
METHODS 
 
37
4.3.2 Preparation of competent cells 
 
 
 
 
 
 
 
 
 
 
 
 
This is modified method from Inoue et al., 1990. In 25 ml LB culture (containing 50 µg/ml 
streptomycin) a single colony from agar plate was inoculated and incubated at 37 °C with 
shaking till the OD600 reaches 0.07 to 0.1. (This usually takes overnight). Next day 0.5 ml 
culture was inoculated in 400 ml LB media and grown at 18 °C till OD600 reached 0.6. The 
culture was equally divided into two centrifuge tubes and incubated on ice for 10 min. The 
culture was then centrifuged at 4800 rpm for 10 min at 4 °C. The pellet was resuspended in 
40 ml TB buffer followed by incubation on ice for 10 min. The culture was centrifuged at 
3200 rpm for 10 min at 4 °C. The pellet was homogeneously resuspended in 10 ml of 
DMSO mix (9.3 ml cold TB + 0.7 ml DMSO, RT) and kept at 4 °C for 10 min and finally 
divided into 0.2 ml aliquots and immediately transferred to liquid nitrogen. The can be 
stored for long term at -80 °C.  
 
 
4.3.3 Determining degree of competence 
 
The high degree of competence is an essential prerequisite to find the correct clone out of a 
ligation mixture. Good competent cells have degree of competence between 1x107-1x 108. 
Colony number counted next day. The degree of competence can be calculated as follows 
107 degree is considered good and denotes the amount of colony to be formed for each µg 
of the pUC18 or pBluescript DNA transformed. The degree of competence was checked 
with the help of following flow-chart. 60 µl has 5 pg of DNA transformed and should in 
produce 100 colonies to achieve 107 degree of competence.  
 
 
 
TB Buffer 
PIPES   10 mM 
CaCl2   15 mM 
KCl            250 mM 
MnCl2   55 mM 
PH adjusted to 6.7 with KOH 
LB Media 
Bacto tryptone 10g/l 
Yeast extract   5 g/l 
NaCl   10g/l 
PH adjusted to 7.5 and  
autoclaved 
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200 µl bacteria were incubated with 1ng of pUC18 
 
 
 
Transformation was carried out and 1 ml cold LB added was incubated at 37 °C for an hour 
 
 
 
 
 
 
 
 
 600 µl was plated     600 µl 
 
 
 
 
 
 
 
 60 µl                   120 µl  300 µl       plated 
 
 
4.3.4 Preparation of glycerol stock 
 
Bacterial cells were stored for long-term use at -80 °C by preserving in glycerol which was 
used as a cryoprotectant. (Ausubel et al., 1989) 
 
 
 
 
 
 
 
For instant availability, bacteria were preserved at 4 °C in agar in Petri plate containing 
appropriate concentration of antibiotics.  
 
 
4.4 Culture and transfection of mammalian cells 
 
Cell growth conditions were already standardized. All cell culture work was performed in 
cell culture facility. 
Glycerol Stock 
Bacterial suspension 10% 
Glycerol  40% 
LB media  60% 
Stored at -80 °C 
Agar Plates 
Bacto tryptone 10 g/l 
Yeast extract    5 g/l 
NaCl   10 g/l 
Agar   15 g/l 
PH adjusted to 7.5 and  
autoclaved 
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The eukaryotic cells used in the study grow in an anchorage-dependent manner however 
CaP cell lines do not exhibit contact inhibition and therefore can grow into clustered if left 
unpassaged. Cells were generally maintained in 145 diameter maxi dishes with 15 ml of 
appropriate media. Depending on their growth behaviour the cells were splitted one to 
three times per week. In order to split the cells, the media was first aspirated off and then 
cells were washed with 1x PBS. The PBS was also aspirated off and 2 ml trypsin 
(invitrogen) was added to cells from the side of the dish. The cells were incubated for 2-4 
min at 37 °C dependent on the strength of adherence of cells. The cells were mixed with 10 
of culture media and gently mixed and divided in a new dish, high or low depending on 
their use. The cells were transferred to 5% CO2 incubator for growth. 
 
 
 
 
 
 
 
 
4.4.1 Preparation of T-media 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 Colony formation assay 
 
The assay carries a goal to test the effect of overexpression of the protein in question on the 
abilities of cells to form colonies in a cell culture dish. The assay was carried out in 10 cm 
cell culture dish. 0.5 Million C4-2 cells were grown for at least 48 hrs before transfection. 
The cells were transfected using calcium phosphate method with a total of 10 μg of DNA 
expressing protein of interest along with the expression vector providing the ability to 
Cell line  Passage  
CV1   thrice weekly 
PC3-wtAR  Once weekly 
C4-2    twice weekly 
LNCaP  Once weekly 
Ingredients   quantity   Final concentration 
DMEM (1g/l glc)   400 ml    80% 
F-12     100 ml    20% 
Supplements 
Insulin     1 ml of 2.5 mg/ml  5 μg/ml 
T3     1 ml of 6.825 ng/ml  13.6 pg/ml 
Apo-transferrin   1 ml of 2.5 mg/ml  5 μg/ml 
Biotin     1 ml of 0.125 mg/ml  0.25 μg/ml 
Adenine    1 ml of 12.5 mg/ml  25 μg/ml 
Penicillin/ streptomycin  5 ml    100 U/l; 100 µg/ml 
FBS     50 ml    10% 
HEPES, pH 7.5   12.5 ml of 1 M  1 mM 
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transfected cells to grow in antibiotic hygromycin thereby selecting transfected cells. Non-
transfected cells eventually die in a couple of weeks. The transfected cells were washed 
after 24 hrs and the media was changed. 24 hours later, cells were treated with 
hygromycin, hormones and inhibitors. The cells were washed with 1x PBS and the media 
was changed twice a week. After death of all non-transfected cells (2 weeks), the 
transformed clones overexpressing the protein started growing to form colonies. They were 
further allowed to grow for 6-8 weeks. The number of colonies obtained was counted and 
the cells were trypsinised and frozen at that point for future usage. 
 
4.4.3 Preparation of hormone-depleted serum 
 
For LNCaP and C4-2 cells  
500 ml thawn FBS was mixed with 25 gms of active charcoal and mixed on a magnetic 
stirrer for 1 hr at RT. The charcoal was pelleted by centrifuging at 7500 rpm for 15-30 min 
and repeated in a new tube. The FBS was filtered with 0.45 μ filter to avoid charcoal 
particles followed by sterile filtering using 0.22 μ filter and stored at -20 °C. 
For CV1 the FBS was first heat inactivated by incubating at 56 °C for 30 min. 
 
4.4.4 Calcium phosphate-based transfection method 
 
The calcium phosphate protocol (Wigler et al., 1978) was used to analyse both transient 
and stable expression of genes. In this protocol a calcium phosphate/DNA precipitate was 
formed which adheres to the surface of adherent cells and was taken up by the cells via a 
poor defined endocytosis.  
 
A total of 216 μl of DNA-transfection mix per well of a six well plate 
 
DNA-transfection mix: 
 
 
 
 
 
 
 
 
 
Scheme for transfection for each of Six well 
 
H2O/DNA  183.6 μl  Make the Total DNA concentration 5.4 μg using Calf thymus 
  DNA 
10xHEBS  21.6 μl  Vortex mix 
2 M CaCl2 10.8 μl  Vortexed for 10 seconds, 10-20 min RT, Vortex and add to 
cells  
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Calculated amount of water was taken and 1 to 5.4 μg of plasmid DNA was dissolved in 
water and added 21.6 μl of 10x HEBS. Vortexed and added 10.8 μl of 2M CaCl2 and 
incubated for 15 min at RT for crystal formation. The mix was directly pipetted. The media 
was changed after 16 hrs and cells were incubated for another 24 to 72 hrs depending on 
the requirement of the experiment. 
 
4.4.5 DOTAP Transfection protocol 
 
Use of HEPES buffer free media is recommended 
 
Cells were seeded out in normal media in one well of a six-well plate (with antibiotics and 
serum) and allowed to reach 60 to 70% level of confluence. 2.5 μg of DNA was diluted and 
a media free of antibiotics and serum to a final concentration of 0.1 μg/μl. 
Pipetted 16 μl DOTAP in a fresh sterile polystyrene tube and adjusted the volume to 50 μl 
by the addition of media free of antibiotics and serum.  DNA solution was mixed gently 
with the DOTAP mix and incubated at RT for 10-15 min. The solution was carefully 
transferred to cells grown in a media containing serum free of antibiotics. 
 
4.4.6 Determining the transfection efficiency  
 
In any kind of transfection the goal is to achieve the maximal possible uptake of DNA by 
as many cells as possible. It is required to test especially the effect of ectopically expressed 
protein on the test system. Many methods are in use.  The method used during the work 
was tested for their transfection efficiency. Transfection efficiency is routinely tested by 
employing an expression plasmid coding for peGFP (enhanced green fluorescent protein) 
inside the cells. 16 hrs after Transfection with the methods to be evaluated cells were 
washed with PBS and media was changed. 72 hrs later cells were visualised under the 
phase contrast microscope to visualize the cells giving peGFP signal in the form of 
emitting green fluorescent light. For C4-2 cells, it turns out that at least 4-5 times better 
Calcium Chloride Solution  
CaCl2 2 M  
Filter sterilized and stored at -20 °C. 
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transfection efficiency (~18-20%) can be achieved with calcium phosphate method 
compared to DOTAP Transfection protocol. It is also observed that the kind of serum,   
normal or depleted, had no effect on the transfection efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1 Determination of transfection efficiency using GFP. Photomicrographs of C4-2 cells 
transfected with eGFP. The microscopic images show the relative efficiency of the two commonly 
used Transfection methods for C4-2 cells. 2 µg of peGFP plasmid for each well of a six-well plate 
was transfected. On right side cells showing green emission represent those which were transfected. 
Panel A and B represent cells transfected using media containing normal serum with Calcium 
phosphate and DOTAP method respectively. Panel C and D represent the cells transfected in media 
containing stripped serum using calcium phosphate method and DOTAP method respectively. 
 
 
 
 
 Dark field Bright field
A
B
C
D
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4.4.7 Cryopreservation of mammalian cells 
 
 
 
 
 
 
 
 
Cells were trypsinised and 10 ml normal media added. Cells were then transferred into a 
fresh 15 ml falcon and centrifuged to spin down. After centrifugation, the media was 
aspirated off and the cell pellet was resuspended in 1 ml of normal media by gentle 
shaking. Then, 1 ml of the cryo media was added and mixed by inverting. Out of this 2 ml, 
1.8 ml media containing cells were transferred to the cryovial which was then kept in a 
small cooler used to gradually cool down the cells to avoid cold damage. The cooler was 
transferred at least for a couple of day to the –80 °C after which the cryovials were 
transferred to liquid nitrogen tank. 
 
4.4.8 Reviving mammalian cells 
 
The cells stored in cryovial were taken out in a 15 ml falcon and 10 ml media was added. 
After gentle mixing cells were briefly centrifuged, supernatant media was discarded and 
the cell pellet was resuspended in 10 ml of fresh media and transferred to a maxi cell 
culture dish in total 15 ml volume and transferred to incubator. 
 
4.4.9 Cell counting using Neubauer chamber 
 
Using a Pasteur pipette a small fraction of cells was transferred to the Neubauer chamber 
and cells were cover slipped and counted at least in three 16X squares and the average was 
taken. The average was divided by 16 and multiplied by the constant 2.5 x 105. This gave 
the number of cells in each ml of the trypsinised cells. 
 
 
4.5 Firefly luciferase assay 
The firefly luciferase assay is most often used these days in nuclear hormone research to 
check the strength of transcription from a given receptor in the presence of 
hormone/inhibitor. The luciferase cDNA fused to a hormone responsive promoter is 
Cryopreservation Media 
FBS  40% 
DMSO  15% 
Media  45% 
METHODS 
 
44
 
 
 
 
 
 
 
 
expressed on the activation of receptor and forms the luciferase enzyme which can be 
measured using a Luminometer and the appropriate substrate. The amount of enzyme 
formed represents the activity of the receptor in vivo. The reaction requires Luciferin, ATP, 
coenzyme A, Mg++ and oxygen. Light emitted by the reaction of enzyme on the substrate 
Luciferin is measured by luminometry. 
Briefly, the transfected cells were lysed using 400 μl of the lysis buffer for 15 min at RT 
and the probes were stored on ice until all samples were collected. 50 μl of sample was 
then read by Luminometer which pumps in 100 μl of the luciferase substrate buffer and 
measures the luciferase units which can be represented in the form of the graph. 
 
4.6 β-Galactosidase assay 
 
 
 
 
 
 
 
 
 
The reporter plasmid pCMV-LacZ contains a gene that codes for the enzyme β-
galactosidase. The CMV promoter is presumed to be unaffected by nuclear hormone 
receptor mediated transcriptional activation and hence transfected as an internal control in 
order to normalize Luciferase values. The method uses a substrate o-Nitro-phenol-β-
Galacto pyranoside (ONPG) which is converted into yellow coloured o-nitro phenol which 
can be photometrically measured at 420 nm. 
Z Buffer  
Na2HPO4 60 mM 
 NaH2PO4  40 mM 
KCl  10 mM 
MgSO4     1 mM 
PH calibration 7.0 + 2.7 ml β-
Mercapto ethanol per Liter 
1 M potassium phosphate solution pH 7.0 
1M K2HPO4  6.15 ml 
1M KH2PO4  3.85 ml 
Filled up to 100 ml with Milli Q. 
ONPG Substrate solution 
4 mg/ml ONPG in 0.1 M potassium 
phosphate with pH 7.0 
Lysis Buffer   
Tris-Acetate PH 7.8     50 mM  
MgAc     10 mM  
EDTA    0.1 mM  
Triton X-100    1 %  
DTT     4 mM  
PMSF     0.2 mM  
DTT and PMSF freshly added to the 
lysis buffer 
Luciferase Substrate Solution  
Tris-Acetate PH 7.8  50 mM  
Luciferin   360 μM  
ATP    1 mM  
Coenzyme A   400 μM  
METHODS 
 
45
In a fresh 1.5 ml reaction tube 600 μl of Z-buffer was taken and mixed with 100 μl of cell 
lysate. To the mix ONPG solution was added. The mix was shaken vigourously and 
incubated at 37 °C in a water bath till yellow. The absorbance was taken at 420 nm. The 
measurement of product formed was done according to the following formula. 
 
Units  
 
 
4.7 Chromatin immuno precipitation 
 
4.7.1 Protein cross linking and chromatin preparation 
 
Cells (LNCaP and C4-2) were grown to 95% confluence, taking into account that before 
harvesting they were grown in hormone-depleted media for at least 48 hrs if the 
experiment was done for hormone studies. Cells were treated with the hormone for the 
required period of time. It is prudent to change the media a couple of hours before treating 
with hormone as it may make the cells relatively more synchronised. If the experiment 
requires the treatment with inhibitor it was done at least 24 hours before harvesting.  
 
 
 
 
 
 
 
In order to cross link proteins with the chromatin, 37% formaldehyde was directly given to 
the media so that the end concentration in the media becomes 1%. The cells were then 
incubated with formaldehyde for exactly 10 min at 37 °C incubator. To stop over-cross 
linking the cells were treated with 2 M glycine (end concentration 125 mM) for 5 min at 
RT which was given directly into the media. The media was aspirated off and the cells 
were washed twice with cold PBS. This was followed by addition of 1.5 ml cold PBS 
containing protease inhibitor cocktail PIC (Complete mini, Roche) and the cells were 
scraped off into a fresh 15 ml falcon and were spun down at 4000 rpm for 5 min at 4 °C. 
The supernatant was discarded and the cells at this point were frozen at -80 °C. The pellet 
ChIP Dilution Buffer 
Triton X-100  1% (v/v) 
EDTA   2 mM 
NaCl          150 mM 
Tris/HCl, PH 8.0       20 mM 
SDS Lysis Buffer 
SDS   1.0% (w/v) 
EDTA   10 mM 
Tris/Cl PH 8.0  50 mM 
                              OD420 x 1000 
       LacZ units = 
       time (in min) 
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(from two maxi cell culture dishes) was resuspended in 2 ml of cold SDS-lysis buffer 
containing protease inhibitor cocktail. Cells were then sonicated to isolate and shear 
chromatin to fragments of desired size. For generating ~500 bp fragments (for LNCaP and 
C4-2) cells were sonicated 10-12 times with 10 sec pulse and 10% output (Branson sonifier 
250). Sonication of each sample was performed at an interval of 1-2 min in order to avoid 
froth formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Schematic representation of Chromatin immuno precipitation (ChIP) assay. 
Chromatin-associated proteins are cross linked. Cells are harvested and chromatin prepared into 
appropriate sized fragments. Chromatin is used for immuno precipitation with specific antibodies 
and complex isolated following which the cross linked proteins are separated from the chromatin 
and subsequently digested. The chromatin is purified and used for the detection of DNA elements 
using known primer sequences. 
 
The sonicated cells were centrifuged at 5800 rpm at 4 °C for 10 min. The soluble 
chromatin remained in the supernatant while the cell debris settled down in the form of 
pellet. The supernatant was then diluted to 10 ml using ice cold ChIP dilution buffer 
containing protease inhibitor cocktail. The diluted chromatin was incubated with 40 μl of 
Protein cross-linking
Immunoprecipitation
Reversing cross-linking and 
digest proteins
DNA purification and 
Quantitative PCR
Chromatin Shearing
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protein A sepharose/salmon sperm DNA for 1 hr on a rocking platform at 4 °C. This step is 
called preclearing the chromatin by allowing all non specific proteins to bind to beads prior 
to incubation with specific antibodies and thereby lowering the possibility of false-positive 
results. Out of this 10 ml small portion (200 µl) was taken as input control. 
 
4.7.2 Immuno precipitation (IP)  
 
 
 
 
 
 
 
 
 
 
 
From the above step the beads were spun down by brief centrifugation at 4 °C. The cleared 
supernatant was used for immuno precipitation with specific antibodies. 1.5 ml of the 
diluted chromatin was incubated overnight (at least 6 hours) at 4 °C on a rocking platform 
to allow antibodies to bind to specific proteins (immuno precipitation). After incubation 35 
µl of sepharose beads were added and the incubation continued further for 3 1/2 hours as 
before. The samples were centrifuged at 2000 rpm for 2 min at 4 °C and the supernatant 
discarded. The beads were sequentially washed with the following buffers with each 
washing followed by 10 min incubation on a rocking platform for 10 min and subsequent 
centrifugation at 2000 rpm for 2 min at 4 °C. 
 
> 1x 1ml of low salt wash buffer 
> 1x 1ml of high salt wash buffer 
> 1x 1ml of LiCl wash buffer 
> 2x 1ml of TE buffer 
 
To the beads left after the last wash, 100 μl of freshly prepared elution buffer was added. 
The 1.5 ml reaction tubes were kept for 15 min on a fixed vortex machine at RT. The 
Low Salt Buffer    
SDS           0.1% (w/v) 
Triton X-100  1% (v/v) 
EDTA     2 mM 
Tris/HCl, PH 8.0  20 mM 
NaCl             150 mM 
High Salt Buffer  
SDS          0.1% (w/v) 
Triton X-100   1% (v/v) 
EDTA   2 mM 
Tris/HCl, PH 8.0 2 mM 
NaCl        500 mM 
LiCl Buffer 
LiCl     0.25 M 
NP-40    1% (v/v) 
Deoxycholate    1% (w/v) 
EDTA      1 mM 
10 mM Tris/HCl, PH 8.0 
Elution Buffer 
SDS  1% (w/v) 
NaHCO3 0.1 M 
Freshly prepared 
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samples were again spun at 2000 rpm for 2 min at 4 °C and the supernatant was collected 
in a fresh 1.5 ml reaction tube. The above elution was repeated with 100 μl of elution 
buffer. The elute was combined together and to each 200 μl sample, in order to reverse-
cross linking, 8 μl of 5 M NaCl was added, mixed by vortexing and kept overnight (To 50 
μl input, 150 μl elution buffer was added mixed and reversed the cross linking with NaCl). 
After overnight incubation each sample was treated with 4 μl 500 mM EDTA + 8 μl 1M 
Tris-Cl pH 6.5 + 1 μl of 10 mg/ml Proteinase K + 1 μl of 10 mg/ml RNaseA. The samples 
were further incubated for 3 hrs at 55 °C. The DNA was purified using QIAquick PCR 
purification kit to perform qPCR. 
 
4.7.3 Chromatin purification for PCR 
 
All centrifugation steps were performed at 13.000 rpm at RT. 200 µl combined elute was 
mixed with 1 ml of PB and mixed by vortexing. The column was placed on the provided 2 
ml tube. Half of the elute (600 µl) was pipetted to the column and spun for 30-60 sec. The 
supernatant was discarded and the rest 600 µl was again pipetted to the previously used 
column and centrifuged once again. The column was washed with 0.75 ml of wash buffer. 
After discarding the wash buffer column was again centrifuged for additional 1 min the 
column was kept on a fresh 1.5 ml reaction tube and 50 µl of EB buffer was poured in the 
centre of the column matrix and allowed incubation for 1 min The reaction tubes were 
centrifuged and the elute containing DNA can be used for performing PCR. 
 
4.7.4 Design and Standardization of ChIP PCR 
 
In order to get the end result of a ChIP experiment PCR was subsequently performed. The 
primers spanning the response elements were selected based on the known complementary 
sequence in the DNA. The primers were generated by using a high output Genefisher 
program available as ftp and online operated at bibiserv.techfak.uni-bielefeld.de/genefisher. 
The primers employed in ChIP study were all designed in a way that they lead to the 
generation of approx. 500 bp PCR products which could be run in 1% agarose gel and 
visualized on UV-trans illuminator. The PCR was standardized primarily by manipulating 
the annealing temperature while keeping the extension temp. and denaturation temp. same. 
The key to obtaining single and specific product lies in the Tm of the primers and the 
annealing temp. was always chosen to be 5 to 10 °C higher than the Tm. This worked 
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nicely in fulfilling the objective. Additionally, PCR could be standardized by employing 
Gradient PCR, where simultaneous amplification of the same PCR reaction mixture took 
place at different annealing temperatures. This program is available on the Peqlab thermal 
cycler available in the laboratory. All ChIP experiments therein have been reproduced. 
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5. Results 
The research work pursued here provides an insight into how target genes expression is 
regulated by androgen receptor (AR). The work shows how interaction of corepressor 
SMRT with AR is decreased in cell type specific manner. The work also shows how Src 
and related kinases potentially enhance AR function on its target genes and can positively 
stimulate growth of prostate cancer (CaP). Further this works identifies a new corepressor 
LCoR for AR. It demonstrates the role of LCoR in repressing AR function and CaP 
growth. The work sheds light on how LCoR function is attenuated by signal transduction 
pathway which results in enhanced AR activity.  
 
 
 
 
5.1 Plasmid construction 
 
For the work undertaken many plasmids were constructed. Briefly the cDNA/part of cDNA 
was taken out from the parent vector and cloned into another acceptor vector in correct 
orientation to the desired promoter that eventually drives the expression of cDNA. cDNA 
fragments were cloned into a polylinker site of the expression vector that contains a series 
of restriction sites for cloning different cDNA with choice of various reading frame, an 
essential prerequisite for the production of a functional proteins. 
All plasmids were sequenced to confirm their correctness. The following description shows 
how the cDNA from donor DNA was cloned into the polylinker site of the acceptor 
plasmid. It shows the resistance that they carry for a particular antibiotic, helping in the 
identification of bacteria carrying them thereby maintaining the purity in subsequent 
usages. 
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Clone Chart:   pSG5-hARK385E, K518E 
 
 
Cloning strategy: 
 
Nru1 + Hind III (0.6 kb fragment) from p5HbAR K385E, 
K518E into Nru1 + Hind III/ CIAP treated pSG5 
 
Selection: 
 
Ampicillin 
 
 
 
 
 
pSG5-AR
6.8 kb
amp r
Poly A
F1 ori
EcoRI
BamHI
SacI
EcoRI
BglII
PvuII
SV40 
ori
pUC ori
hAR cDNA
NruI reg.                                               HindIII reg.
K385E
K518E
pT7
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Clone Chart:   pAB-gal94 LCoR 
 
 
Cloning strategy: 
 
Nhel, Klenow, EcoRV fragment (1,3 kb) from pCMV-VP-
LCoR into pAB gal94-linker Eco 47III, CIAP treated 
Selection: 
 
Ampicillin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RSV
LTR
amp r
pABgal94-linker
4.2kb
SV40
ori
Poly Aga
l
NdeI
NdeI
NcoI
SspI
EcoRI
SspI
ScaI
StuI
EcoRI
KpnI
BglII
SmaI
LCoR
Eco47III/EcoRV                        Hind III            PvuII Acc1           Nhe1/ Eco47III
BamHI
HindIIIPvuII
XhoI
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Clone Chart:   pCS2-MT-LCoR 
 
 
Cloning strategy: 
 
NheI, Klenow, EcoRV fragment (1.3 kb) from pCMV-VP-
LCoR into EcoRI, Klenow, and CIAP treated pCS2-MT 
 
Selection: 
 
Ampicillin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pCS2+MT
4.3 kb
amp r
Poly A
F1 ori
HindIII
BamHI
SV40 
ori
ColE1 Ori
SP6 
6 myc
tags
LCoR
EcoRI/EcoRV HindIII PvuII AccI NheI/EcoRI
T7
XhoI
XbaI
StuI
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Clone Chart:   pAB-VP-DBD 
 
 
 
Cloning strategy: 
 
TthI, Klenow, KpnI fragment from pABgal94-linker 
Into KpnI + Eco47 III digested pAB-VP-AB-505 
 
 
Selection: 
 
Ampicillin 
 
 
pAB-VP16-AR505
3.9 kb
Poly A
NcoI
NdeI
SV40 
ori
RSV
LTR 
SspI
ScaI
EcoRI
amp r
SspI
VP16 DBD AR
KpnI reg.                               EcoRI SmaI HindIII TthIII/Eco47III
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5.2 Regulation of target gene expression in prostate cancer cells 
 
AR mediates the biological effects of androgens. Activated AR translocates to the nucleus 
and bind to the cis- regulatory consensus elements for the binding of AR (called Androgen 
response elements, AREs). Binding to AR attract coactivators and/or corepressors in order 
to build transcription permissive or repressive complexes resulting in the modulation of 
target gene expression. The following section addresses the direct regulation of androgen 
target gene by AR and its corepressors. 
 
5.2.1 In vivo recruitment of AR and its corepressors on positively-regulated target 
genes in CaP cells 
 
AR-mediated transactivation involves its recruitment of AR to the androgen response 
element (AREs) in the regulatory region of target genes. PSA gene expression is known to 
be positively stimulated by AR and AR binding has previously been shown to this element 
(Young et al., 1992). Prostate stem cell antigen (PSCA) gene was shown to be positively 
regulated by androgens and an ARE has been found in its enhancer region (Jain et al., 
2002). PSCA is a cell surface marker and is overexpressed in CaP (Reiter et al., 1998). 
Anti-PSCA monoclonal antibodies inhibit tumour growth and metastasis formation and 
prolong the survival of mice bearing human prostate cancer xenografts (Saffran et al., 2001 
and Watabe et al., 2002). Therefore, PSCA is emerging as an important diagnostic marker 
and therapeutic target in CaP. However, direct in vivo involvement of AR and its 
corepressors in regulating PSCA expression has not been addressed. 
Target gene regulation by AR often involves coactivators and corepressors. To test the 
possibility of direct regulation of PSCA expression by AR and its corepressors in vivo, 
ChIP analyses were performed. LNCaP and C4-2 cells were grown in androgen-deprived 
media and treated with R1881 (10-8 M), CPA (10-7 M) and Cas (10-7 M) for 1 hr. 
Afterwards, chromatin was prepared and immuno precipitated with antibodies against AR, 
corepressor SMRT and Alien. Subsequently, PCR was performed with specific primers 
designed based on the known DNA sequence spanning putative AREs to detect the binding 
of AR, SMRT and Alien under various AR ligands (Fig. 5.1). Under positive control 
conditions upon no hormone treatment (referred as control) in LNCaP cells, on PSA 
enhancer element, binding of AR and both of its tested corepressors, Alien and SMRT was 
observed. Upon treatment with agonist R1881, the recruitment of AR was enhanced while 
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that of corepressor SMRT was lost. It also resulted in strong recruitment of corepressor 
Alien. Treatment of LNCaP cells with partial agonist CPA also induced enhanced AR 
recruitment on this element. In addition, CPA treatment also led to strong recruitment of 
corepressor SMRT and Alien in line with a previous report (Dotzlaw et al., 2002). Cas 
treatment however led to loss of AR recruitment on PSA enhancer in concordance with 
recent data suggesting that Cas treatment of androgen-independently growing cells lead to 
association of AR to nuclear matrix (Whitaker et al., 2004) and that Cas treatment  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1 AR and corepressor SMRT and Alien are recruited to the regulatory elements in the 
target genes. A. Schematic representation of the regulatory regions in the androgen target genes. 
PSA promoter contains two separate AREs situated app. 0.2 and 0.4 kb upstream of the 
transcription start site. PSA enhancer situated -4.0 kb upstream also contains a functional AREs. 
PSCA enhancer contains an ARE situated 2.7 kb upstream of the transcription start site. Presence 
of an ARE situated 0.3 kb upstream in the maspin promoter. B. 0.75 Mi LNCaP cells were seeded 
out in CSS containing RPMI 1640 medium and C4-2 cells were seeded in CSS containing T-media 
containing normal serum. Cells were grown for 4 days after which the fresh CSS T-media was 
given. Cells were further grown for 48 hrs and were treated with ligands R1881 (10-8 M), CPA (10-7 
M) and Cas (10-7 M) for 1 hr. after which ChIP procedure was followed. The immuno precipitated 
DNA fragments were purified and subjected to amplification by specific primers spanning the 
AREs in the corresponding response element. The figure shows the result of a ChIP experiment. 
 
interferes with the recruitment of AR to its target sites (Farla et al., 2005). Similar results 
from ChIP experiment on PSCA were obtained (Fig. 5.1). On PSCA enhancer AR binding 
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was enhanced in response to R1881 and that of SMRT was decreased. Under conditions of 
CPA treatment, Alien was strongly recruited, while the binding of AR and SMRT 
remained unchanged compared to no hormone conditions. These results indicate that both 
PSA and PSCA are target genes for direct AR action and their expression might be 
modulated by the corepressors recruited to AR under the influence of various ligands. 
However, AR recruited is to PSCA enhancer in presence of Cas. This is in contrast to loss 
of AR binding observed under Cas treatment on PSA enhancer raising the possibility that 
antagonistic action of ligands on AR action may well vary in part by the differences in the 
response elements. ChIP experiment performed in C4-2 cells on PSCA enhancer element 
revealed that AR recruitment was marginally enhanced by R1881 and remained unchanged 
in presence of CPA or Cas. Binding of corepressor SMRT was only marginally enhanced 
in response to CPA, however remained unchanged by R1881 or Cas.  
 
5.2.2 In vivo recruitment of AR and its corepressors on maspin promoter element 
 
The Maspin is a member of serine protease family and a tumour suppressor implicated in 
inhibition of tumour progression and invasion (Cher et al., 2003). Maspin expression is 
known to be negatively modulated by androgens, in addition, maspin, a tumor suppressor 
was identified to be expressed in prostate and is negatively regulated by androgens (Zhang 
et al., 1997). In vitro binding assays and transfection experiments revealed the binding of 
AR to these AREs elements. Here, the recruitment of AR and corepressors and their 
molecular actions are poorly understood. ChIP data show the recruitment of corepressors 
SMRT and Alien on key target genes (previous section). The possibility of direct binding 
of AR and its corepressors was also explored on maspin promoter element. ChIP 
experiments were performed in LNCaP and C4-2 cells under similar conditions as 
mentioned in the previous section. Maspin promoter is known to contain an ARE which 
has been shown to interact with AR in vitro. Results indicate that under conditions without 
any hormone (referred as control), both AR and Alien were recruited (Fig. 5.2). Treatment 
of LNCaP cells with R1881 enhanced the binding of corepressor Alien and led to the 
abolishment of AR binding. Upon CPA treatment binding of Alien and AR is decreased 
however, the recruitment of SMRT is seen. Interestingly, under conditions of Cas 
treatment, the recruitment of AR was decreased while that of Alien remained unchanged. 
Similarly, the ChIP experiment was performed in C4-2 cells and the immuno precipitated 
DNA was subject to amplification with primers spanning maspin putative AREs. In C4-2 
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cells under conditions without any hormone treatment recruitment of corepressor AR and 
AR was observed, in addition binding of SMRT is also observed. R1881 treatment led to a 
marginal decrease in binding of AR and both of the corepressors tested, Alien and SMRT. 
Upon treatment of C4-2 cells with CPA, surprisingly, the binding of AR and corepressors 
SMRT and AR was completely abolished. Cas induced loss of AR and SMRT recruitment, 
parallely decreasing the recruitment of Alien.  
Results obtained in the absence/presence of R1881 are in contrast to those obtained for 
PSA and PSCA. On positively regulated PSA and PSCA, R1881 promoted the recruitment 
of AR (Fig. 5.1), contrarily, R1881 induced loss of AR recruitment on maspin promoter in 
LNCaP cells and significantly decreased AR recruitment in C4-2 cells. This indicates that a 
differential  recruitment of hormone-bound AR  depends in part on the  nature  of  response  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2 AR and corepressors are differentially recruited to maspin promoter in response to 
various AR ligands. (A) Graphical representation of maspin promoter element and the position of 
AREs. (B) 0.75 Mi LNCaP/C4-2 cells were seeded out in RPMI1640/T-media containing normal 
serum respectively. Cells were grown for 4 days after which the fresh CSS containing RPMI/T-
media was given. Cells were further grown for 48 hrs and were afterwards treated with ligands 
R1881 (10-8 M), CPA (10-7 M) and Cas (10-7 M) for 1 hr. after which ChIP procedure was 
followed. The immuno precipitated DNA fragments were purified and subjected to amplification 
by specific primers spanning the AREs in the corresponding response element. The figure shows 
the result of a ChIP experiment. 
 
element. Similar decrease or loss of AR recruitment was observed in response to partial 
agonist CPA in LNCaP and C4-2 cells respectively. This suggests that agonist/partial 
agonist -bound AR confirmation is unstable on the maspin response element in contrast to 
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strong AR recruitment by R1881 on a positive regulatory element. However, Cas treatment 
led to loss of AR recruitment on maspin promoter. 
 
5.2.3 Differential effect of CPA on PSCA and maspin expression in C4-2 cells 
 
Previous section focused on determining regulation of AR and its tested corepressors 
SMRT and Alien recruitment under the influence of various ligands. To determine the 
influence of CPA treatment on the expression of PSCA and maspin genes, real time PCR 
was performed. Effect of partial antagonist CPA was tested on the expression of PSCA and 
maspin in mRNA level in androgen-dependently growing C4-2 cells. C4-2 cells growing in 
6-well culture plates were treated for 48 hrs with CPA (10-7 M). RNA was isolated using 
Trifast reagent, reverse transcribed to cDNA and was subjected to amplification by light 
cycler using primers specific for PSCA and maspin mRNA and results were normalised 
using GAPDH. Treatment of C4-2 cells with partial antagonist CPA decreased expression  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3 Contrasting effect of partial antagonist CPA on the expression of PSCA and maspin 
mRNA in CaP cells. 200.000 C4-2 cells/well of the six well tissue culture dish were seeded out in 
CSS containing T-media. 24 hrs later cells were treated with CPA (10-7 M) for 48 hrs. Afterwards 
total cellular RNA was isolated, reverse transcribed to cDNA and was subjected to amplification by 
light cycler using specific primers and internal control primers against GAPDH. The graph 
represents the GAPDH normalised values of the PSCA and maspin transcripts. 
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of PSCA (Fig. 5.3) gene, which is positively regulated by androgens advocating that CPA 
shows only marginal inhibitory effect in repressing AR transactivation of target genes. The 
same RNA preparations were used for real time PCR using maspin primers. Contrasting to 
results obtained for PSCA, CPA led to enhanced expression of maspin transcripts further 
highlighting the contrasting regulation of PSCA and maspin genes by AR in C4-2 cells. 
ChIP data (fig 5.2) in fact reveals the loss of CPA-bound AR binding to maspin element in 
C4-2 cells.  
Add together, the results from ChIP and real time PCR experiments demonstrate that 
PSCA and maspin are oppositely regulated by AR signaling. It suggests that AR 
recruitment on maspin promoter in the absence of hormone repress maspin expression. 
However, loss of AR recruitment from this element leads to its enhanced expression. 
 
5.3 Src kinase inhibition decreases AR transactivation and the growth of 
androgen-independently growing cells 
 
Kinase cascades are known to be overexpressed in different kinds of cancer. e.g., in breast 
cancer cells, Src kinase leads to failure of antagonistic action of Tamoxifen (Shah et al., 
2005). Failure of CaP anti-hormone therapy may also involve action by Src. In fact, Src is 
over expressed in androgen-independently growing CaP cells and correlate with the 
increased metastatic potential of cancer cells (Slack et al., 2001). This part focused, 
therefore to determine the possible role of Src in modulating AR function and the growth 
of CaP cells. 
 
5.3.1 Inhibition of Src by PP2 decreases AR transactivation in C4-2 cells 
 
The ability of Src kinase to modulate AR transactivation function was tested using 
luciferase reporter assays in androgen-independently growing C4-2 cells in vivo. Cells 
were transfected with MMTV-Luc and PSA-Luc androgen responsive reporters and 
pCMX-LacZ which was used as an internal control. AR-mediated transactivation was 
repressed by treatment of cells with Src inhibitor PP2 (Fig. 5.4). To test whether 
attenuation of AR transactivation by PP2 on target genes expression is a promoter-specific 
phenomenon or AR function is in general reduced; two different AR target elements, 
MMTV and PSA, were used. Indeed AR transactivation potential was reduced to almost 
50% on both MMTV and PSA reporter elements. This suggests that in androgen-
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independently growing cells AR function on its target genes is still important. To test, 
whether PP2-mediated decrease in target gene expression is due to decrease in AR 
transactivation  of  its  target  genes or  the  decrease in  target gene  expression  in  general  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4 Inhibition of Src kinase by chemical inhibitor PP2 leads to decrease in AR 
transactivation of target genes in C4-2 cells. 300.000 C4-2 cells were seeded out in normal serum 
containing T-media. 24 hrs later cells were transfected with 1.0 µg each of MMTV-luc and PSA-
luc reporter plasmids along with 0.2 µg of pCMV-LacZ which was used as an internal control to 
normalize transfection efficiency. After washing, cells were treated with 1 µM PP2 for 72 hrs. Cells 
were lysed and luciferase values were measured. Values obtained without the inhibitor in each case 
were set as 1. The graph represents the activation of reporter expression as LacZ normalized 
relative luciferase units. 
 
irrespective of the promoter, the effect of PP2 was tested on the expression of another 
control gene driven by CMV enhancer. The C4-2 cells were transfected with pCMV-LacZ 
reporter plasmid and treated with PP2 similar to the above experiment. In fact, the 
expression of this gene remained unaffected by PP2 treatment (Fig. 5.5) suggesting that the 
PP2 specifically decreases AR transactivation on its target genes. The enhanced 
transactivation by AR observed in C4-2 cells is in part boosted by overexpression of Src 
kinase as evident from inhibitor experiment and which may decrease the response to anti-
hormone therapy. This may act as a potential growth-inhibition escaping mechanism 
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adopted by CaP cells for sustained growth. In fact AR activity has been shown to be 
subject to regulation by many signaling kinases including Her2 (Craft et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5 PP2 does not affect expression of β-galactosidase in C4-2 cells. 300.000 C4-2 cells were 
seeded out in normal serum containing T-media. 24 hrs later cells were transfected with 0.2 µg of 
pCMV-LacZ which was used as an internal control to normalize transfection efficiency. After 
washing, cells were treated with 1 µM PP2 for 72 hrs. Cells were lysed and β-galactosidase values 
were measured and graph plotted. 
 
 
5.3.2 Src inhibition leads to decreased recruitment of AR on target genes in vivo 
 
To determine the effect of Src inhibition on AR recruitment to its target genes, chromatin 
immuno precipitation (ChIP) assay was performed. C4-2 cells were treated for 48 hrs with 
Src inhibitor PP2 (1 µM), following which cells were treated with R1881 (10-8 M) for 1 hr. 
The nucleo protein complexes were immuno precipitated with anti-AR and anti-IgG 
antibodies and purified DNA fragments were subsequently amplified by PCR with primers 
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Fig. 5.6 Src inhibition leads to decreased AR recruitment on its target genes. 0.75 Mi C4-2 
cells were seeded out in T-media containing normal serum. Cells were grown for 4 days after 
which they were grown for 48 hrs in T-media containing CSS and were simultaneously treated with 
1µM PP2 for 48 hrs. Before lysis, cells were treated with ligands R1881 (10-8 M) for 1 hr. after 
which ChIP procedure was followed. Prior to immuno precipitation, part of chromatin was saved 
that functions as input here. Rest was immuno precipitated with anti-AR antibody or normal rabbit 
IgG that acts as negative control for the experiment. Fragments were purified and subjected to 
amplification by specific primers spanning the enhancer region of PSA containing ARE. After 
PCR, amplified products were run on 1% agarose gel, visualised by UV light and pictured by the 
gel documentation system, the figure shows the result of a ChIP experiment. 
 
for PSA enhancer. In concordance to the recruitment of AR observed on PSCA element in 
the absence of R1881 (section 5.2.1, fig. 5.1) AR recruitment was also observed on 
androgen-responsive PSA enhancer in the absence of R1881 (Fig. 5.6). Treatment of C4-2 
cells with R1881 led to increase in AR recruitment. Intriguingly, C4-2 cells pre-treated 
with Src inhibitor exhibited drastic loss of AR recruitment on PSA enhancer in the absence 
of R1881. However, AR was strongly recruited upon treatment of PP2-pre-treated cells 
with R1881. These experiments indicate that recruitment of AR to its target genes is indeed 
subject to regulation by PP2-mediated Src inhibition. This also suggests that decrease in 
reporter gene expression by chemical blockade of Src (sec. 5.3.1) may potentially involve 
decreased recruitment of AR in the presence of PP2. However, PP2-mediated decrease in 
AR recruitment was overcome by R1881 to similar level as seen in the absence of PP2.  
 
 
 
 
PP2
R1881 
- - + +
- +    - +
IgG Control
α-AR
INPUT
RESULTS 
 
64
5.3.3 Effect of PP2-mediated Src inhibition on in vivo target gene expression 
 
In order to test the effect of Src blockade on target gene expression, real time RT-PCR 
experiment was performed. Briefly, C4-2 cells were treated with PP2 (1 µM) for 48 hrs. 
The following day cells were treated with R1881 (10-10 M). 24 hrs later cells were 
harvested and RNA isolation was performed. The prepared RNA was subjected to reverse-
transcription to synthesize cDNA, which was used for performing real time amplification 
with   primers   specific   for   PSA   gene.  Values   were  normalized   to    actin     control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.7 Src kinase inhibition by PP2 leads to loss of agonist induced PSA mRNA induction in 
C4-2 cells. 200.000 C4-2 cells/well were seeded out in CSS containing T-media in six well tissue 
culture dishes. 24 hrs later cells were treated with R1881 (10-10 M) for 48 hrs. Afterwards total 
cellular RNA was isolated, reverse transcribed to cDNA and was subjected to amplification by light 
cycler using specific primers and control primers against Actin. The graph represents the actin 
normalised values of the PSA transcripts. 
 
It is evident from this experiment that C4-2 cells show a basal leaky expression of PSA 
gene transcripts in the absence of agonist R1881 (Fig. 5.7) which may be explained largely 
by the agonist-independent recruitment of AR on PSA enhancer. In fact PSA gene is 
marginally expressed in C4-2 cells even in the absence of agonist and the expression has 
been shown to go up upon agonist treatment (Jia and Coetzee, 2005). Treatment with 
R1881 led to further 3-fold induction of PSA gene transcripts, in agreement of enhanced 
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AR recruitment under that condition (Fig. 5.6). Interestingly, R1881-mediated induction of 
PSA mRNA expression, however, was lost in C4-2 cells pre-treated with PP2. The real 
time experiments are not in total agreement to ChIP experiment.  
Taken together, results from transient transfection, real time and ChIP experiments suggest 
that a basal level of PSA transcripts are expressed in C4-2 cells in the absence of agonist.          
Agonist R1881 leads to enhanced AR transactivation function on target genes reflected in 
the induction of PSA gene transcription. PP2-mediated blockade of Src suggests that 
induction of PSA transcription by AR in response to agonist is significantly contributed by 
Src signal transduction pathway, blocking which leads to decrease in AR target gene 
expression (Fig. 5.4) and induction (Fig. 5.7) as well. Treatment of C4-2 cells growing in 
androgen-depleted T-media with Src kinase inhibitor PP2 alone however, leads to loss of 
AR recruitment, surprisingly no further decrease in PSA gene transcript was observed. 
This suggests that the C4-2 cells express basal level of PSA mRNA independent of AR 
transactivation function. However, induction of PSA expression by AR requires not only 
enhanced AR occupancy but Src-mediated signaling plays an important role in AR 
transactivation leading to enhanced PSA expression. 
The hAR is synthesized as a single 110 kDa protein, which becomes rapidly 
phosphorylated to a 112 kDa protein (Brinkmann et al., 1992). AR is a phosphoprotein and 
is heavily phosphorylated not only by signal transduction machinery-mediated cross-talk 
independent of agonist, but AR is phosphorylated in response to agonist that leads to 
conformational changes and receptor activation. Indeed, AR is known to interact with Src 
kinase in response to agonistic ligand (Kousteni et al., 2001) it is possible that certain 
phosphorylation sites in AR are phosphorylated by a subset of kinases while others are 
subject to phosphorylation by other signal kinase stimuli. Phosphorylation of various 
domains may have different functional consequences on receptor activation. In fact Src 
kinase is known to be overexpressed in CaP and enhances the AR function at very low 
concentration of agonist R1881 (Castoria et al., 2003) suggesting that it enhances the  
transactivation function of AR and may also cooperate in its ability to bind to target genes.  
 
5.3.4 Src kinase blockade by PP2 decreases in C4-2 cell growth 
 
The functional consequence of PP2-mediated decrease in AR transactivation and loss of 
induction of target gene expression in response to agonist was tested in relation to cellular 
growth. C4-2 cells were grown in T-media containing 10% normal serum (serum which 
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has not been depleted of androgens) and were treated with PP2 (1 µM) with media change 
twice a week for a period of 6 weeks and thereafter the effect of PP2 on cellular growth 
was tested. Treatment of  C4-2 cells  leads to reduced  growth of  cells in response  to  PP2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.8 Src kinase inhibition leads to decrease in growth of C4-2 cells. 200.000 C4-2 cells were 
cultured in 10 cm tissue culture dishes in T-media containing 10% normal serum for a period of 6 
weeks. Cells were given fresh media twice a week along with 1 µM PP2. After 6 weeks cells were 
counted and pictures using light microscope assisted camera. The graph shows relative cell number 
(each triplicate). 
 
(Fig. 5.8). While untreated cells grow to form a homogeneous monolayer with small 
intercellular spaces, Src inhibitor PP2 treated cells show retarded growth and an explicit 
decrease in cell number. 
Taken together these results indicate that androgen-independently growing cells do depend 
on AR-mediated signaling for growth. This also employs that enhanced AR transactivation 
observed in androgen-independently growing C4-2 cells is in part contributed by over 
expression of Src signal transduction pathway. This also suggests that CaP cells achieve 
androgen-independent growth in part by overexpressing Src kinase. In essence, the results 
implicate the role of Src kinase in enhancing AR transactivation on its target genes. This 
induction is blocked by PP2-mediated Src blockade, in part by decreased AR 
transactivation on its target genes thereby allowing decrease in cellular growth. 
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5.4 Molecular characterization of interaction of corepressor SMRT with 
endogenous AR in LNCaP and C4-2 cells: the role of signaling cascades 
 
CaP cells exhibit strong AR transactivation and enhanced cellular growth, suggesting 
decreased/lost influence of corepressors in inhibiting AR function. AR activity is known to 
be regulated by corepressor SMRT function (Dotzlaw et al., 2002, Liao et al., 2003). 
Indeed tyrosine kinase signaling is known to negatively regulate the interaction between 
SMRT and TR (Hong and Privalsky, 2000). Similarly PKA signaling which is known to 
activate AR, inhibits the binding of SMRT to AR (Dotzlaw et al., 2002). Reports also 
suggest that SMRT function is potently inhibited by MAPK cascade that operated 
downstream of the growth factor receptor. Activation of MAPK leads to SMRT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.9 Graphical representation of mammalian-one-hybrid to detect interaction of 
corepressor SMRT with AR in vivo. Upper panel shows the graphical representation of 
corepressor SMRT, which contains four repression domains (RDs) and two receptor interaction 
domains (RIDs). Lower panel shows the methodology of Mammalian-one-hybrid. C-terminus 422 
aa of corepressor SMRT were expressed as a fusion protein along with VP16 transactivator. The 
ligand-regulated interaction of SMRT with AR brings VP16 into the close proximity of promoter 
allowing a strong activation of the reporter luciferase gene and the product formed can directly be 
measured using Luminometer. 
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phosphorylation and its nuclear import (Hong and Privalsky, 2000) indicating that SMRT-
mediated AR repression is influenced by signal transduction. To test the influence of 
signaling cascades in regulating AR and SMRT interaction, mammalian-one-hybrid assay 
was performed. The assay utilized a hybrid protein, which retains the receptor interaction 
domains of SMRT (Fig 5.9) deleting the repression domain, fused to a potent viral 
transactivator protein VP16.  The system works on a simple principle- interaction of 
corepressor SMRT with AR, brings VP16 into the close proximity of the target gene 
promoter allowing expression of the luciferase gene (fig 5.9) and the strength of interaction 
can be quantitatively measured by the amount of luciferase units obtained under a given set 
of conditions. 
LNCaP cells were cotransfected with VP16 empty vector or VP16-cSMRT along with 
MMTV-Luc reporter. pCMV-LacZ was used as internal control (Fig. 5.10). In LNCaP 
cells the binding of AR with VP16-cSMRT fusion protein was not observed in vivo in 
CPA-dependent manner (Fig. 5.10 A). It is possible that abruptly activated signal 
transduction machinery may influence this interaction. Experiment indicate that indeed 
interaction was enhanced significantly on co-treatment of cells with PRK-1 inhibitor 
HA1077 (Fig. 5.10 B), or MAPK inhibitor U0126 (Fig. 5.10 C) and Src kinase inhibitor 
PP2 (Fig. 5.10 E) in a CPA-dependent fashion. In contrast, the treatment with tyrosine-
kinase inhibitor AG1517, did not lead to enhancement of interaction of SMRT with 
endogenous AR in LNCaP cells (Fig. 5.10 D). Rather AG1517 treated LNCaP cells 
showed a general decreased in reporter activation and induction. These results indicate that 
abrupt activation of specific signal transduction cascades in CaP cells may function in 
multiple ways to allow the growth of CaP cells. Loss of interaction of corepressor SMRT 
with AR by signaling cascades identified by using inhibitors may allow target gene 
expression and growth of cells leading to failure of CPA-based anti-hormone therapy. 
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Fig. 5.10 Interaction of corepressor SMRT with AR in LNCaP cells is differentially 
modulated by signal transduction pathways. 300.000 LNCaP cells were seeded out in androgen-
deprived T-media and were transfected with MMTV-luc (1 µg), 0.22 µg of empty vector VP16 or 
VP16-cSMRT. pCMX-LacZ (0.4 µg) was used as internal control. 16 hrs after transfection media 
was changed with androgen-deprived fresh RPMI 1640 media and were treated with CPA (10-7 M) 
alone (A), or co treated with PRK inhibitor HA1077 1 µM, (B), MAPK inhibitor U0126 1 µM (C),  
tyrosine kinase inhibitor AG1517 1 µM (D) and Src inhibitor PP2 also 1 µM (E) for a period of 72 
hrs. Cells were lysed and luciferase values were measured. Experiment was conducted in triplets 
and values obtained for VP16 empty vector in the absence of any inhibitor were arbitrarily set as 1. 
The graph represents the activation of reporter expression as LacZ normalised relative luciferase 
units. 
 
 
On the other hand, Experimental results indicate 3-fold increase in SMRT interaction with 
AR in C4-2 cells in a CPA-dependent manner over values obtained for empty vector VP16, 
in the presence of CPA (fig 5.11 A) raising the possibility that signal transduction 
pathways may act differentially to regulate interaction of corepressor SMRT interaction in 
cell-type specific manner. It is notable that two different tyrosine kinase inhibitors PP2 and 
AG1517 were used. AG1517 inhibits the membrane tyrosine kinase and therefore blocks 
many essential growth factor signals and inhibits the growth not only of the LNCaP cells 
but also the reporter expression as evident from Fig. 5.11 D. PP2 in contrast being more 
specific and inhibits non-receptor cytosolic tyrosine kinases such as focal adhesion kinase 
(FAK). 
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Fig. 5.11 in vivo interaction of corepressor SMRT with endogenous AR is regulated by signal 
transduction pathway in a CPA-dependent manner in C4-2 cells. 200.000 C4-2 cells were 
seeded out in androgen-deprived T-media and were transfected with MMTV-luc (1 µg), 0.22 µg of 
empty vector VP16 or VP16-cSMRT. pCMX-LacZ (0.4 µg) was used as a internal control. 16 hrs 
after transfection media was changed with androgen-deprived fresh RPMI 1640 media and were 
treated with CPA (10-7 M) alone (A), or cotreated with PRK inhibitor HA1077 1 µM, (B), MAPK 
inhibitor U0126 1 µM (C),  tyrosine kinase inhibitor AG1517 1 µM (D) and Src inhibitor PP2 also 
1 µM (E) for a period of 72 hrs. Cells were lysed and luciferase values were measured. Experiment 
was conducted in triplets and values obtained for VP16 empty vector in the absence of any 
inhibitor were arbitrarily set as 1. The graph represents the activation of reporter expression as 
LacZ normalized relative luciferase units. 
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Intriguingly, PRK1 inhibitor HA1077 did not alter interaction of SMRT with AR in vivo 
(Fig. 5.11 B) However, the same inhibitor promoted interaction of SMRT with AR in 
LNCaP cells (fig 5.10 B). Similarly MAPK inhibitor U0126 did not modulate interaction 
of SMRT with AR in C4-2 cells (Fig. 5.11 C). Interestingly receptor tyrosine-kinase 
inhibitor AG1517 and non-receptor tyrosine kinase inhibitor PP2, both led to loss of 
SMRT interaction in C4-2 cells (Fig. 5.11 D & E) presumably by functionally inactivating 
SMRT interaction with AR through a phosphorylation-mediated mechanism. This further 
emphasizes the differential behaviour of signaling kinase in regulating corepressor 
interaction with AR in cell type-specific manner. 
 
 
5.5 Characterisation of LCoR as a transcriptional corepressor for AR  
 
5.5.1 LCoR represses wt AR in a ligand-dependent manner 
 
LCoR was identified as an interaction partner in a screen for protein that interacted with 
the LBD of ERα (Fernandes et al., 2003). Transient transfection experiments were 
performed to test the ability of LCoR to modulate AR function. Report suggests that AR 
bound to various ligands shows different functionality in terms of its interaction with 
corepressor molecules (Dotzlaw et al., 2002) by allowing a slightly different conformation 
of AR LBD. Whether wt-LCoR is able to repress wt-AR transactivation function under the 
influence of various ligands was therefore tested. Activated AR by synthetic agonist 
R1881, partial antagonist CPA and natural hormone DHT as drastically repressed upon 
cotransfection of LCoR suggesting that LCoR can act as AR corepressor not only in an 
agonist-dependent manner (Fig. 5.12) but also in a partial agonist CPA-dependent manner. 
Cas and OH-F which act as pure antagonist for wt-AR did not allow higher transactivation 
by wt-AR and therefore LCoR-mediated transcriptional corepression on wt-AR can not be 
envisaged.  
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Fig. 5.12 wt-LCoR represses wt-AR in a ligand-dependent fashion. 90.000 CV1 were seeded 
out in androgen deprived DMEM media and cells were transfected with pMMTV-Luc (1 µg), hAR 
(0.2 µg) and 1 µg each of pSG5 (control) and pSG5-LCoR. 0.4 µg pCMV-LacZ was used as an 
internal control. 16 hrs post-transfection, cells were treated with R1881 (10-10 M), CPA (10-7 M), 
DHT (10-7 M), Cas (10-7 M) or OH-F (10-7 M) for 72 hrs following which cells were lysed, 
luciferase measurement was done and graph was plotted arbitrarily setting control in the absence of 
hormone as 1. The experiments were conducted in triplets and the graph represents fold reporter 
activation as LacZ normalised relative luciferase units. 
 
 
LCoR has been shown to repress GR, PR and ER by interacting with their LBDs involving 
its NR box and a mutant form of LCoR where its NR box with sequence motif LXXLL  
was  exchanged  with  LSKAA  (called LCoR-mut, fig. 5.12 A)  led  to  loss   of  
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Fig. 5.13 LCoR-mut represses wt-AR in a ligand-dependent fashion. (A) Graphical 
representation of LCoR NR box and LCoR-mut. (B) 90.000 CV1 were seeded out in androgen 
deprived DMEM media and cells were transfected with pMMTV-Luc (1 µg), hAR (0.2 µg) and 1 
µg each of pSG5 (control) and pSG5-LCoR. 0.4 µg pCMV-LacZ was used as an internal control. 
16 hrs post-transfection, cells were treated with R1881 (10-10 M) for 72 hrs following which cells 
were lysed, luciferase measurement was done and graph was plotted arbitrarily setting control in 
the absence of hormone as 1. The experiments were conducted in triplets and the graph represents 
fold reporter activation as LacZ normalised relative luciferase units. 
 
repression of these receptors (Fernandes et al., 2003) therefore LCoR-mut. was also tested 
for its ability to repress AR function. In fact, coexpression of LCoR-mut. leads to a robust 
decrease in AR transactivation in agonist-dependent manner (Fig. 5.13 B). 
To determine the minimal concentration of the corepressor with apparently no or very little 
corepressor function transient transfection was performed. Intriguingly however, 
cotransfection of as little LCoR plasmid as 250 ng was sufficient to sharply decrease AR 
transactivation to more than ~50 fold on MMTV promoter in an agonist-dependent fashion 
(fig 5.14). This suggests that LCoR poses a “super repression” on agonist-activated AR 
function. 
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Fig. 5.14 wt-LCoR acts as a transcriptional corepressor for AR. 100.000 CV1 cells seeded out 
in hormone deprived DMEM media and were transfected with pMMTV-Luc (1 µg), wt-AR (0.2 
µg) and varying amount of LCoR shown. 16 hrs post-transfection, media was exchanged with the 
fresh media and cells were treated with synthetic agonist R1881 (10-10 M) for 72 hrs. Cells were 
harvested, luciferase measurement was done and graph was plotted arbitrarily setting values 
obtained for pSG5 in the absence of hormone as 1. The experiment was conducted in triplets and 
the graph represents fold reporter activation. 
 
 
The agonist-independent enhancement of basal luc values for 1 and 2 µg of LCoR suggests 
that higher amounts of this corepressor though not able to interact  and repress AR, can  
nevertheless, squelch some transcription repressor proteins from repressing basal AR 
transactivation in the absence of ligand leading to the higher basal values in the absence of 
ligand.  
 
5.5.2 LCoR also acts as a transcriptional corepressor for mutant ARs in CV1 cells 
 
 
Because many CaP cells, including LNCaP and C4-2, harbour a mutant form of AR-
T877A bearing mutation in the LBD and has been shown recently to positively stimulate 
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the growth of CaP cells (Sun et al., 2006). It is possible that in addition to broadened ligand 
spectrum this mutant may not be repressed by corepressors hence promoting cell growth. 
Therefore transient transfection experiments were carried out to determine whether wt-
LCoR is able to repress T877A mutant of AR in vivo. Similar results were obtained as for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.15 LCoR-wt represses ligand-activated T877A mutant of AR in a ligand-dependent 
fashion. 90.000 CV1 were seeded out in androgen deprived DMEM media and cells were 
transfected with pMMTV-Luc (1 µg), hAR (0.2 µg) and 1 µg each of pSG5 (control) and pSG5-
LCoR. 0.4 µg pCMV-LacZ was used as an internal control. 16 hrs post-transfection, cells were 
treated with R1881 (10-10 M), CPA (10-7 M), DHT (10-7 M), Cas (10-7 M) or OH-F (10-7 M) for 72 
hrs following which cells were lysed, luciferase measurement was done and graph was plotted 
arbitrarily setting avg. values obtained for pSG5 in the absence of hormone as 1. The experiments 
were conducted in triplets and the graph represents fold reporter activation as LacZ normalised 
relative luciferase units. 
 
wt-AR suggesting that T877A mutant activated by agonists R1881 and DHT and partial 
agonist CPA can be repressed by wt-LCoR in ligand-dependent fashion. In contrast, this 
mutant activated by OH-F, which acts as a partial agonist for T877A mutant can also be 
repressed by LCoR (Fig. 5.15). These data suggest that LCoR-mediated repression may be 
independent of the AR conformation attained in presence of various ligands and therefore 
allows repression by LCoR in presence of various AR ligands in CV1 cells. Agonist-bound 
AR is known in general, to bind coactivators which eventually lead to gene expression. 
Agonist-dependent repression of LCoR suggests that LCoR may be a part of negative 
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feedback loop in AR transactivation presumably by competing with coactivators and 
thereby fine-regulation the AR transactivation.  
Next, a double point mutant of AR, which shows very strong transactivation in response to 
ligand (called AR SUMO mutant, K385E, K518E) (Poukka et al., 2000) which does not 
interact with and thereby not repressed by corepressor SMRT and Alien (Dotzlaw et al., 
2002), was tested for LCoR mediated repression. wt-LCoR represses AR SUMO mutant- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.16 wt-LCoR represses AR-Sumo mutant in a ligand-dependent fashion. 100.000 CV1 
were seeded out in androgen deprived DMEM media and cells were transfected with pMMTV-Luc 
(1 µg), hAR (0.2 µg) and 1 µg each of pSG5 (empty vector control) and pSG5-LCoR. 16 hrs post-
transfection, cells were treated with R1881 (10-10 M), CPA (10-7 M), DHT (10-7 M), Cas (10-7 M) or 
OH-F (10-7 M) for 72 hrs following which cells were lysed, luciferase measurement was done and 
graph was plotted arbitrarily setting avg. values obtained for empty vector control in the absence of 
hormone as 1. The experiments was conducted in triplets and the graph represents fold reporter 
activation. 
 
 
mediated transactivation in vivo (Fig. 5.16), raising the possibility that LCoR can indeed 
interact with the AR mutant in a ligand-dependent fashion and that this interaction is not 
dependent on point mutation in AR NTD or LCoR can potentially target another domain of 
AR for its interaction. This indicates that LCoR differs from other corepressors in that it is 
able to repress AR function in a hormone-dependent fashion, may also target an entirely 
different domain of AR for mediating its repression.  
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5.5.3 LCoR interacts with AR in an agonist-dependent manner in vivo 
 
To demonstrate that repression of AR by LCoR involves its direct in vivo interaction with 
agonist-bound AR on its target elements, modified mammalian-one-hybrid assay was 
performed. Our unpublished results (Michaela Patz, Diploma thesis) suggested that the 
CPA-induced binding of LCoR with AR does not require its NR box; rather AR interacts 
via C-terminus of LCoR, which harbours an HLH interaction motif. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.17 LCoR interacts with AR in partial agonist CPA- and agonist R1881-depdendent 
manner. (A) LCoR is a 433 aa residue protein. It has a single NR box for interaction with selected 
members of nuclear hormone receptor superfamily. A centrally situated region is responsible for its 
interaction with HDACs, and another CtBP binding motif is also present. The C-terminal part of 
protein harbours a HLH interaction motif. VP16-cLCoR was constructed by cloning last 332 C-
terminus aa into pCMX-VP16 empty vector. (B) 100.000 CV1 cells were seeded out in androgen-
deprived DMEM were transfected with pMMTV-Luc (1 µg), pCMX-VP16-cLCoR (2 µg) and hAR 
(50 ng). 16 hrs post-transfection, fresh media was given and cells were treated with CPA (10-7 M) 
or R1881 (10-10 M) for 72 hrs. Cells were harvested and luciferase measurements were done and 
graph was plotted arbitrarily setting avg. values obtained for empty vector control VP16 in the 
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absence of hormone as 1. The experiments was conducted in triplets and the graph represents fold 
reporter activation. 
 
Previous report (Fernandes et al., 2003) suggested that LCoR functions as a corepressor in 
agonist-dependent manner for ER, PR etc. It was found (in previous section) that LCoR 
acts as a corepressor for R1881-bound AR as well, therefore the mammalian-one-hybrid 
was aimed at finding whether VP16-cLCoR is able to interact with R1881-bound wt-AR 
was performed. AR shows 7-fold interaction with cLCoR over empty vector VP16 in a 
R1881-depdendent fashion (Fig. 5.17). VP16-cLCoR also interacts with CPA-bound AR, 
used here as a positive control. Taken together, these results indicate, that in order to 
repress AR, LCoR directly interacts in vivo with AR in a ligand-dependent manner, an 
essential prerequisite for a protein to fulfill the criteria to function as a corepressor. 
 
5.5.4 Response element specificity of LCoR-mediated AR repression 
 
PSA and probasin genes are known to be activated by functional AR signaling (Zhang et 
al., 2000 and Cleutjens et al., 1997). Therefore it was important to test the effect of LCoR 
mediated AR repression in context of natural chromatin of AR target genes.  
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Fig. 5.18 Response element specificity of LCoR mediated repression of AR. 100.000 CV1 cells 
were seeded out in androgen-deprived DMEM media and cells were transfected with reporter 
plasmids (1 µg each) of PSA-Luc, Probasin-Luc, GRE-tk2-Luc and PSCA (2,7-3.0)- Luc along 
with 0.2 µg of hAR and 1 µg of pSG5 or pSG5-LCoR. 16 hrs post transfection, media was changed 
and cells were treated with 10-10 M of R1881 for 72 hrs. Cells were lysed and luciferase units were 
measured. (A) LCoR shows agonist-dependent repression of PSA promoter. (B) GRE-tk2-Luc, an 
artificial response element which is responsive to members of nuclear hormone receptor 
superfamily is also repressed in agonist-dependent fashion when LCoR is expressed. (C) androgen-
responsive mouse probasin promoter is also repressed by LCoR in agonist-dependent fashion. (D) 
PSCA promoter activation by LCoR. Graph was plotted arbitrarily setting values in the absence of 
hormone as 1 for each reporter. The experiments was conducted in triplets and the graph represents 
fold reporter activation. 
 
 
 
PSA gene codes for prostate specific antigen in humans and is overexpressed in conditions 
like benign prostate hyperplasia and CaP and therefore is widely used not only for the 
diagnosis of the disease but also to monitor the response of anti-hormone therapy which 
decreases PSA expression in the initial phase of the treatment. 
AR transactivation potential on natural promoters PSA and probasin is significantly 
repressed by the coexpression of LCoR in a hormone-dependent manner (fig 5.18 A & C) 
which highlights the physiological relevance of LCoR to repress AR transactivation, which 
may hence play a protective role against the disease by repressing AR mediated gene 
activation and thereby the growth of CaP. GRE-tk2-Luc, an artificial promoter which is 
responsive to androgens in addition to glucocorticoids is also repressed by LCoR in a 
ligand-dependent fashion (Fig. 5.18 B). Interestingly another AR responsive gene Prostate 
stem cell antigen (PSCA) which is known to be activated by androgens (Jain et al., 2002) 
shows enhanced transcription by LCoR independent of hormone (Fig. 5.18 D), suggesting 
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that there exists promoter specificity in repression of AR by LCoR. These results are 
contrary to the corepression effect on LCoR seen on other elements and on other members 
of NHR (Fernandes et al., 2003). It is known that androgen receptor-mediated expression 
of target gene often involves other -cis elements in addition to AREs as Sp1 and therefore 
it is possible that the minimal PSCA promoter containing 300 bp upstream of transcription 
start site including ARE is not in itself sufficient to be inducible by AR and therefore AR 
may be recruited to this minimal element without exhibiting a strong induction by 
hormone. Indeed transient transfections carried out in CV1 cells with this minimal 
promoter element barely show hormone induction by DHT and only ~2 fold hormone 
induction by synthetic agonist R1881. Presumably therefore, cotransfection of LCoR may 
squelch transcription inhibitory molecules, which are recruited to a feeble functioning AR 
allowing AR to show a little transactivity on this minimal element without hormone 
suggesting that in this particular context LCoR-mediated effect is only an artifact.  
 
5.5.5 LCoR-mediated repression does not involves C or N terminus of AR 
 
 
Corepressors are regulatory proteins that, though by themselves cannot bind to target DNA 
directly, rather can influence the function of NHRs by interacting with various AR 
domains (Baniahmad 2005). e.g., corepressor SMRT targets NTD of CPA-bound AR 
(Dotzlaw et al., 2002), however, other set of corepressors interact with the LBD of AR e.g. 
hRad9 etc. (Wang et al., 2004). In order to interact with NHRs, SMRT and NCoR use a 
“CoRNR”motif with consensus LXXI/LXXXI/L. This is similar in sequence with “NR” 
box of coactivator proteins (Hu and Lazar, 1999). Binding of antagonist exposes a 
hydrophobic cleft in the helix-12 situated in the LBD, which allows the binding of 
corepressors carrying such kind of hydrophobic motif. LCoR also has a motif similar to 
LXXLL motif of coactivator proteins and indeed known to interact with many members of 
NHR superfamily (Fernandes et al., 2003) via their LBD. Therefore, the binding with 
NHRs is disrupted by mutations in this motif called LSKAA resulting in loss of repression 
(Fernandes et al., 2003). Results suggest that LCoR with mutant LXXLL motif is able to 
repress AR transactivation to the same degree as observed by the wt-LCoR in a hormone-
dependent manner (Fig. 5.13 B). Various deletion mutants of LCoR were therefore tested 
for their ability to interact with AR (Michaela Patz, Diploma thesis). These experiments 
suggested that C-terminus aa 101-end, which excludes LXXLL motif is involved in its 
interaction with AR in receptor-negative CV1 cells. In fact the C-terminus of LCoR 
contains a protein-protein interaction HLH (Helix-loop-helix) motif suggesting that LCoR 
RESULTS 
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may use HLH motif to interact with AR. In order to map down the domain of AR that 
facilitates its interaction with LCoR various AR deletion mutants lacking one or few 
functions/domains were used. Various truncations of the N-terminus as well as NTD-
deleted AR mutants were used to map down part of AR protein that interacts with LCoR in 
a hormone-dependent manner. These truncations included Δ39-171 that deletes part of AF1 
ligand-independent transactivation function, Δ39-328 which excludes the N-terminal part 
lacking part of AF1 and TAU5 activation functions. Two other NTD deletions, Δ510-536 
and Δ 447-536 were also included. In addition, a C-terminal deletion which deletes LBD of 
AR was individually transfected along with reporter and AR expression vector.  
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Fig. 5.19 LCoR does not interact with LBD or NTD of the AR in CV1 cells. (A) Various AR 
mutants used to map down interaction domain with LCoR are shown. (B) Cells were transfected 
with pMMTV-Luc (1 µg) along with 1 µg each of pSG5 and pSG5-LCoR.wt. In addition 0.2 µg of 
various AR mutant expression plasmids that lead to truncated AR proteins were also transfected. 16 
hrs post-transfection cells were treated with 10-10 M R1881 for 72 hrs. Afterwards, cells were 
harvested and luciferase activity was measured. Graph was plotted against the arbitrarily set value 
of 1 for control pSG5 obtained in the absence of ligand. ”Δ” indicates the part of the AR proteins 
deducted from the functional protein. 
 
 
As evident from the result, f.l. wt-LCoR was able to repress various AR N-terminus 
truncations (Fig. 5.19 B). These truncations included part of AF1 function and TAU-5 
function, which play decisive role in transactivation imparted by NTD. Similarly, AR 
truncation devoid of the complete LBD was also repressed significantly by coexpression of 
f.l. wt-LCoR. Results indicate that various N- and C-terminal deletions were repressed by 
wt-LCoR. It raises the possibility that LCoR may have two different interaction motifs for 
interaction with AR. (1) By its LXXLL motif it can bind to the LBD of AR as it binds to 
ER, PR, VDR and GR (Fernandes et al., 2003) and (2) and by the C-terminus which 
harbours HLH motif, it may interact with some other domain of the AR. The first 
possibility was ruled out previously (fig 5.13 B) whereby LCoR-mut was able to repress 
wt-AR in a ligand-dependent manner. In order to rule out the possibility of bifacial 
interaction, similar experiments were performed LCoR mutant where LXXLL motif was 
replaced by LSKAA.  
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Fig 5.20 LCoR-mut does not interact with LBD or NTD of the AR in CV1 cells. 100.000 CV1 
cells were seeded out in androgen-deprived DMEM media and were transfected with pMMTV-Luc 
(1 µg) along with 1 µg each of pSG5 and pSG5-LCoR.wt. In addition 0.2 µg of various AR 
mutants expression plasmids that lead to truncated AR proteins were also transfected. 16 hrs post-
transfection cells were treated with 10-10 M R1881 for 72 hrs. Afterwards, cells were harvested and 
luciferase activity was measured. Graph was plotted against the arbitrarily set value of 1 for control 
pSG5 obtained in the absence of ligand. ”Δ” indicates the part of the AR proteins deducted from 
the functional protein. 
 
 
Surprisingly, various AR mutants were robustly repressed by LCoR-mut. as well (5.20), 
excluding the possibility of a bifacial mode of LCoR interaction with AR. Had there been a 
bifacial interaction of LCoR with AR, i.e., 1) Interaction with AR-LBD through its NR 
box, and 2) interaction with other domain(s) through its HLH motif, LCoR would have 
been unable to repress one of the mutant used in the above experiment. This means that 
interaction of LCoR with AR does not involve its “NR” box. These results indicate that a 
different domain of AR, (not LBD) possibly the DBD may be involved in interaction with 
both wt and mutant LCoR. 
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5.5.6 Mammalian-one-hybrid experiments demonstrate wt- and mutant LCoR target 
the DBD of AR in a hormone-dependent fashion 
 
Above experiments, ruled out the possibility of the involvement of AR NTD or LBD as a 
target for LCoR interaction and pointed out towards the DBD of AR to be a potential target 
for interaction and repression by LCoR. Indeed, some coactivators have been shown to 
target the DBD of the AR in order to activate its function e.g., Ubc9 has been shown to 
activate AR function by targeting part of the DBD (Poukka et al., 1999). It is therefore, 
possible that corepressors can target also the same domain to modulate AR transactivation. 
To test this possibility, first another mutant of AR, whereby the entire NTD was replaced 
by VP16- transactivation domain was tested for LCoR-mediated repression. This mutant 
was referred to as VP16-DBD-LBD. Cotransfection of this mutant together with LCoR 
wild type led to the repression of this AR construct in a hormone-dependent manner (Fig. 
5.21 B), suggesting that NTD of AR does not play a role in LCoR-mediated repression. As 
LBD mutant of AR was robustly repressed both by LCoR-wt and LCoR-mut., this 
advocated the potential involvement of the DBD of AR in interaction with LCoR. 
Therefore, to demonstrate the absolute involvement of the DBD in interacting with 
corepressor LCoR, a mutant was generated from the parent vector VP-AR-505 (referred in 
the text as VP16-DBD-LBD) by deleting the LBD, which led to the generation of VP16-
AR-DBD, whereby the DBD of AR is expressed as a fusion protein with VP16 
transactivation domain. This mutant was tested for LCoR-mediated repression in 
mammalian-one-hybrid experiments performed in CV1 cells. Briefly, cells were 
transfected either with VP16 empty vector or VP16-AR-DBD, along with reporter plasmid 
and with or without LCoR-wt or LCoR-mut. As evident, VP16 alone or in combination 
with LCoR-wt or LCoR-mut was incapable to drive the expression of reporter containing 
AREs (Fig. 5.22). Interestingly transfection of VP16-AR-DBD led to very robust 
enhancement of reporter activity attributed to the binding through DBD and transactivation 
mediated by VP16 transactivation domain. Cotransfection of LCoR-wt or LCoR-mut led to 
a dramatic decrease in reporter activity. Because of the lack of LBD any hormone 
induction by R1881 was not seen. 
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Fig. 5.21 LCoR represses the VP16-DBD-LBD mutant of AR in CV1 cells. (A) Graphical 
representation of VP16-AR fusion proteins. (B) 100.000 CV1 cells were seeded out in androgen-
depleted DMEM and were transfected with pMMTV (1.0 µg), VP16 or VP-AR-505 (0.1 µg) and 1 
µg each of either pSG5 or pSG5-LCoR. 16 hrs post transfection media was changed with fresh 
media and cells were incubated with R1881 (10-10 M) for 72 hrs. Afterwards, cells were harvested 
and luciferase activity was measured. Graph was plotted against the arbitrarily set value of 1 for 
control obtained in the absence of ligand. 
 
This data clearly indicate that LCoR indeed targets the DBD of AR in order to interact and 
repress its transactivation function. Research demonstrate that many coregulatory proteins 
despite having motif similar to  “NR” or “CoRNR” motif may not always bind to the AF2 
hydrophobic cleft exposed in response to hormone binding such as coactivator SRC-1 
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which also interacts also in addition to the CAG repeats situated at the NTD of AR (Ma et 
al., 1999). In addition corepressor SMRT, having a CoRNR motif does target the NTD of 
the AR (Dotzlaw et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.22 Both wt-LCoR and LCoR-mut., target DBD of AR in CV1 cells. 100.000 CV1 cells 
were seeded out in androgen-depleted DMEM and were transfected with pMMTV (1.0 µg), VP16 
or VP-AR-DBD (0.1 µg) and 1 µg each of either pSG5 or pSG5-LCoR. 16 hrs post transfection 
media was changed with fresh media and cells were incubated with R1881 (10-10 M) for 72 hrs. 
Afterwards, cells were harvested and luciferase activity was measured. Graph was plotted against 
the arbitrarily set value of 1 for cotransfected empty vector pSG5+VP16 obtained in the absence of 
ligand.  
 
 
These experiments suggest a novel mode of AR repression by corepressor LCoR which 
differs from other members of NHR superfamily where LCoR targets the LBDs. This 
indicates that LCoR is equipped with multiple mode of interaction that varies in receptor 
context further adding intricacy to its repression function. These data also demonstrate,  
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however, that the repression of VP16-DBD alone by LCoR is not as potent as seen for wt-
or other point mutant forms of AR. Individual corepressors are known to form complexes 
with each other e.g., Alien a corepressor for TR functionally interacts and forms complex 
with another corepressor Sin3A (Moehren et el., 2004). In the similar way, SMRT and 
NCoR are known to form complexes with each other, it is possible that LCoR can form 
silencing complex with other corepressors recruited to either NTD of LBD that synergises 
in repressing AR transactivation. It is also possible that VP16 acts as a much stronger 
transactivator compared to the NTD of AR and therefore cannot be completely repressed 
by LCoR hence not allowing it to completely repress the activated DBD-VP16. 
 
5.6 Functional attenuation of LCoR in CaP cells 
 
Many coregulators are post-translationally modified that lead to modulation of their normal 
physiological function. LCoR has been shown to be expressed in CaP cells (Fernandes et 
al., 2003). However, CaP have been reported to show overexpression of AR signaling as 
reflected in PSA expression, a marker for CaP progression (Chen et al., 2004, Gregory et 
al., 2001, Jenster 2000, Viscorpi et al., 1995). The question arises how the presence of such 
a potent ligand-dependent corepressor in CaP is tolerated by CaP cells. It is possible as 
discussed in section 5.4 that LCoR is functionally attenuated by CaP cells using one or 
more strategies, similar to SMRT. That prompted to the investigation whether ectopically 
expressed LCoR is able to interact and thereby repress endogenous AR function in 
androgen-independently growing C4-2 cells.  
 
5.6.1 Cell type-specific regulation of LCoR interaction with AR is modulated by Src 
signal transduction pathway 
 
Results depicted in the previous section demonstrate that LCoR shows a robust repression 
of AR by interacting with it in a ligand-dependent manner in CV1 cells. The ability of 
LCoR to interact with endogenous AR in C4-2 cells was tested by performing mammalian-
one-hybrid assay. C4-2 cells were transfected with VP16 empty vector or with VP16-
cLCoR and MMTV-luc reporter. Intriguingly, these results demonstrate that the binding of 
LCoR to endogenous AR was dramatically reduced in C4-2 cells (Fig. 5.23 A) compared 
to the strong LCoR binding observed in CV1 cells (Fig. 5.17), a possible strategy adopted 
by cells to escape LCoR-mediated AR repression.  
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Many signal transduction pathways are overexpressed in androgen-independently growing 
cells which may potentially decrease this interaction in order to overcome AR repression. 
In C4-2 cells, introduction of dominant-negative Ras restores sensitivity to Casodex (Bakin 
et al., 2003). Similarly, treatment of C4-2 cells with Her2 tyrosine kinase inhibitor, AG825 
leads to apoptosis in C4-2 cells but the same amount was not able to induce apoptosis in 
LNCaP cells indicating that overexpression of Her2 may provide androgen-independence 
to C4-2 cells. Therefore a battery of chemical inhibitors of specific signal transduction 
pathways was employed to test the effect of blockade of specific signaling pathway on 
interaction of AR with LCoR in C4-2 cells. As evident from the experiment blocking Src 
kinase signaling using its chemical inhibitor PP2 leads to enhanced interaction of LCoR 
with AR in C4-2 cells (Fig. 5.22 A). These results demonstrate that Src signaling 
functionally  interferes  with  the  binding  of   LCoR to  AR   in vivo. To test  whether  this   
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Fig. 5.23 Src kinase regulates interaction of LCoR with AR in CaP cells in a cell type-specific 
manner. (A) 300.000 C4-2 cells (B) 100.000 PC3-wt AR cells were seeded out in androgen-
depleted T media and DMEM media respectively. Following day, cells were transfected with 
MMTV-Luc (1 µg), VP16 or VP16-cLCoR (1 µg for C4-2, 2 µg for PC3-wt AR) along with 0.4 µg 
of pCMV-LacZ which was used as an internal control. 16 hrs post transfection cells fresh media 
was given and cells were treated with R1881 (10-10 M) and Src inhibitor PP2 (1 µM) for 72 hrs. 
Afterwards, cells were harvested and luciferase measurements were done and graph was plotted 
arbitrarily setting each empty vector control VP16 in the absence of hormone as 1. The experiments 
were conducted in triplets and the graph represents fold reporter activation as LacZ normalised 
relative luciferase units. 
 
 
Src-mediated decrease  in  LCoR interaction is a common strategy adopted by androgen-
independently growing cells or is specifically harnessed by C4-2 cells, similar mammalian-
one-hybrid assay was performed in PC3-wtAR CaP cells that grow in an androgen-
independent manner. In PC3-wtAR cells, LCoR shows interaction with AR in a ligand-
dependent manner (Fig. 5.23 B), similar to that seen in C4-2 cells, suggesting a marginal 
interaction in both cell lines. In contrast to enhanced interaction of LCoR observed with 
AR in C4-2 cells by Src blockade, treatment of transfected PC3-AR cells with PP2 led to 
loss of LCoR interaction with AR. These data indicate that decreased LCoR interaction 
with AR in C4-2 cells by Src kinase may be a cell type-specific phenomenon specifically  
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adopted by C4-2 cells, to escape LCoR-mediated repression, to allow loss of regulation of 
AR transactivation and thereby growth in an androgen-dependent fashion.  
 
5.6.2 Regulation of LCoR autonomous silencing function in a cell-type specific 
manner  
 
Many repressor proteins act as autonomous silencers to suppress transcription. LCoR has 
been shown to function as an autonomous transcription corepressor (Fernandes et al., 
2003). It is possible that the repression function can be regulated in cell type-specific 
manner, a full length LCoR was fused to Gal-DBD to test its repressional effect on Gal-
responsive promoter element (called p(UAS)4-TATA-Luc). In addition other corepressors 
namely NCoR and Alien were also tested. Experiments were carried out in CV1 and in C4-
2 cells. Results obtained from CV1 cells indicate that corepressor Alien shows 3-fold 
repression over control Gal empty vector however; corepressor NCoR and LCoR shows a 
potent repression function on the gal-responsive promoter (Fig. 5.24 A). This strong 
repression by LCoR explains largely its strong repressional effect seen on AR (Fig. 5.14) 
in a ligand-dependent manner in CV1 cells. Intriguingly however, similar experiment in 
C4-2 cells showed that LCoR repression function is severely compromised (Fig. 5.24 B). 
The observed decrease in LCoR repression potential may involve signal transduction 
cascades which may phosphorylate LCoR and decrease its repression function that may 
still allow LCoR to maintain its interacting function with AR but can compromise its 
silencing function. Similar decrease was observed in the repression potential of another 
corepressor NCoR in C4-2 cells. However, no change was observed in Alien repression 
potential in both cell lines. These results indicate a novel mechanism that CaP can utilise to 
weaken specific corepressors at multiple levels. In addition to decreasing the interaction of 
corepressor with AR, the repression potential can also be attenuated to minimise the effect 
of corepressor on the AR. 
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Fig. 5.24 Autonomous silencing function of LCoR is severely retarded in CaP cells compared 
to CV1 cells. (A) 100.000 CV1 cells (B) 300.000 C4-2 cells were seeded out in androgen-depleted 
DMEM and T media respectively. Following day, cells were transfected with p(UAS)4TATA-Luc 
(1 µg) reporter containing Gal binding sites along with 1 µg each of Gal-Alien, Gal-NCoR and Gal-
LCoR plasmids. 16 hrs post transfection fresh media was given and cells were treated with R1881 
(10-10 M) and Src inhibitor PP2 (1 µM) for 72 hrs. Afterwards, cells were harvested and luciferase 
measurements were done and graph was plotted with respect to values obtained for empty gal. The 
experiments was conducted in triplets and the graph represents fold reporter repression over gal 
control. 
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It is possible that all corepressors in general show reduced repression function in CaP cells 
due to activated signaling kinases and that it is not LCoR specific phenomenon, to rule out 
this possibility, another corepressor “Alien” which is acts as a corepressor for selected 
members of NHR superfamily and it has been shown that Alien is a phosphorylation target 
by PKA pathway (Dotzlaw et al., 2002) therefore, was included to test whether its 
repression potential is also regulated by Src kinase. As is evident from the experiment, 
LCoR shows a dramatic decrease in its repression potential in C4-2 cells compared to CV1 
cells (Fig. 5.24 B), however the repression shown by Alien remains unchanged indicating 
that autonomous repression potential of LCoR is specifically decreased by Src kinase and 
the cancer cell uses specific signaling machinery in order to functionally inactivate its 
repression function thereby providing a growth stimuli to cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.25 Src kinase signal transduction pathway decreases LCoR repression function in CaP 
cells. 300.000 C4-2 cells were seeded out in androgen-depleted T media. Following day, cells were 
transfected with p(UAS)4TATA-Luc (1 µg) reporter containing Gal binding sites along with 1 µg 
Gal-LCoR plasmid. 16 hrs post transfection fresh media was given and cells were treated with 
R1881 (10-10 M) and MAPK inhibitor U0126 (1 µM), LY294002 (1 µM) and Src inhibitor PP2 (1 
µM) for 72 hrs. Afterwards, cells were harvested and luciferase measurements were done and graph 
was plotted with respect to values obtained for each empty gal. The experiments was conducted in 
triplets and the graph represents fold reporter repression over gal empty vector control. 
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Therefore, the role of signal transduction pathways was tested to explain weakened 
repression potential of LCoR in C4-2 cells. C4-2 cells were transfected with Gal-DBD 
fused LCoR and Gal responsive luciferase reporter. A battery of signal transduction 
inhibitors was tested for its effect on LCoR repression function. Gal-LCoR showed feeble 
repression  of   Gal-responsive luciferase  promoter (Fig. 5.25). Inhibition of  MAPK using 
inhibitor U0126, did not alter its repressional potential. In addition, blocking PI-3K kinase 
by LY294002 led to a marginal increase in LCoR repression. Interestingly however, 
blocking Src kinase using specific chemical inhibitor PP2 led to a sharp increase in the 
autonomous repression potential of LCoR.  
Taken together, results obtained by these experiments clearly indicate that activating 
signaling kinases can indeed influence corepressor LCoR function and that this functional 
inactivation by signaling kinases may act at multiple levels. In case of LCoR, Src kinase 
not only decreases its interaction with AR, as evident from mammalian-one-hybrid 
experiments (Fig. 5.23 A), but also attenuates its autonomous repression function (Fig. 
5.24 B), which may work in synergy to functionally attenuate LCoR from acting as a 
potent corepressor in CaP cells. Src-kinase mediated signaling may potentially play a role 
by post-translationally modifying LCoR by means of phosphorylation of its tyrosine 
residues which may play an important role in LCoR repression function. Indeed sequence  
 
Tyrosine predictions 
 
Name  Position  Context  Score  Prediction 
 
S1  12        FAAEYTSKN  0.818  *Y* 
S2  200        AKPHYEFNL  0.955  *Y* 
S3  273        TGDQYSYSS  0.603  *Y* 
S4  325        SGQPYPTSD  0.526  *Y* 
S5  384        STLEYKVKE  0.589  *Y* 
 
Fig. 5.26 LCoR sequence analysis. Predicted tyrosine residue(s) in its aa sequence, which are 
potential phosphorylation targets by tyrosine kinases. The score against each sequence represents 
the probability of phosphorylation with the “1” theoretical value obtained for an experimental 
phosphorylation. Y is a one word abbreviation for tyrosine (Source: Netphos 2.0 Bioinformatics 
server, Technical University of Denmark). 
 
 
analysis of LCoR suggests many potential residues which can be phosphorylated by 
tyrosine kinases and might lead to its functional inactivation (Fig. 5.26). However a 
function point mutation-based analysis is lacking. 
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5.6.3 Decreased AR repression in CaP cells: Implications of signal transduction 
 
AR signaling promotes the growth of normal prostate and progression of CaP and the 
therapy carries therefore the goal to repress AR function. Corepressors also repress AR 
function and therefore have been suggested to protective effect against CaP. In fact 
corepressors are known to be functionally recruited to antihormone CPA-bound AR to 
repress its function (Dotzlaw et al., 2002). In this direction, the ability of LCoR was tested 
to repress endogenous AR in androgen-independently growing C4-2 cells. Briefly, C4-2 
cells were co transfected with AR responsive reporter plasmid along with LCoR expression 
vector. In fact, LCoR-mediated AR repression is dramatically reduced in C4-2 cells (fig 
5.27). This was a puzzling phenomenon observed because the same T877A mutant of AR 
is able to be strongly repressed in CV1 cells (Fig. 5.15). This decreased effect of LCoR can 
however be explicitly explained on the basis of (1) decreased in vivo interaction of LCoR 
with AR (2) decreased autonomous repression potential of LCoR in C4-2 cells by Src 
signal transduction pathway. Therefore experiment was conducted to test the effect of Src 
inhibition by PP2 on LCoR-mediated AR repression in C4-2 cells. The repression of AR 
by LCoR was significantly enhanced in a ligand-dependent fashion upon cotreatment of 
cells with Src kinase inhibitor PP2 (Fig. 5.27). These results indicate that indeed, C4-2 
cells, by over expressing Src kinase specifically inhibit LCoR to function as AR 
corepressor. 
These experiments suggested that the repression potential of LCoR is significantly 
compromised in CaP cells, presumably as a part of sustained growth promoting strategy 
adapted by CaP cells. 
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Fig. 5.27 LCoR-mediated AR repression is attenuated and PP2-mediated blockade of 
Src kinase strengthen LCoR-mediated AR repression in C4-2 cells. 300.000 C4-2 cells 
were seeded out in androgen-depleted T media. Following day, cells were transfected with MMTV-
Luc (1 µg) reporter plasmid, pSG5 or pSG5-LCoR (1 µg) and pCMX-LacZ (0.4 µg; internal 
control). 16 hrs post transfection fresh media was given and cells were treated with R1881 (10-10 
M) and Src inhibitor PP2 (1 µM) for 72 hrs. Afterwards, cells were harvested and luciferase 
measurements were done. The experiments were conducted in triplets and the graph represents fold 
reporter activation as LacZ normalised relative luciferase units. 
 
 
5.7 Modulation of CaP cell growth by LCoR 
 
5.7.1 LCoR inhibits growth of androgen-independently growing C4-2 cells and 
promotes neuroendocrine differentiation 
 
Prostate cancer is an endocrine cancer that involves anomalies in AR function. Many CaP 
grow hormone-independently and regress upon anti-hormone therapy that antagonises the 
receptor function. In many therapy resistance cancers, however, the tumour becomes 
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androgen-independent and therefore leads to therapy failure, in some other cases of CaP, 
upon long-term Cas treatment, the AR pathway is bypassed (Hobisch et al., 2006) means  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.28 LCoR represses cell growth and induces neuroendocrine transdifferentiation in 
androgen-independently growing C4-2 cells. (A) Light microscope photographs of C4-2 cells 
grown in T-medium containing normal serum. C4-2 cells were seeded out at the density of 200.000 
cells per 10 cm tissue culture dish. Cells were transfected with pSG5 empty vector or pSG5-LCoR 
along with pETE vector in 5:1 molar ratio employing calcium phosphate transfection protocol. 
Cells were selected with 200 µg/ml hygromycin over a period of 6 weeks with continuous fresh 
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media change twice a week. (B) C4-2 cells were numbered for colonies formed. Average of the 
triplicate was taken and the graph was plotted. 
 
that AR becomes promiscuitely/constitutively active. As previously described, both kinds 
of tumours though depend on functional AR signaling and regress upon AR depletion. It is 
known that AR, in addition to promoting growth of CaP cells, also suppresses neuro-
endocrine differentiation of CaP AR function cells (Wright et al., 2003) and AR knock 
down using siRNA leads to a neuro-endocrine phenotype that manifest itself by inducing 
dendrite-like cellular processes. Corepressor which represses may thereby also lead to 
neuro-endocrine differentiation in addition to decreased CaP growth. Therefore the ability 
of LCoR to repress C4-2 cellular growth was also tested. Clones of C4-2 cells stably 
overexpressing LCoR were generated. Cells with control vector or LCoR expression 
vector, in combination with pETE (which provides resistance to hygromycin, Protopopov 
et al., 2002) were cotransfected and selected over a period of 6 weeks on hygromycin (200 
µg/ml) in normal serum-containing T-media. LCoR overexpression in C4-2 cells led to 
inhibition of growth (Fig. 5.28). Cells overexpressing LCoR produce less colonies 
compared to those transfected with empty vector pSG5, indicating the potential growth 
inhibitory effect of the corepressor on cellular growth. The morphological analysis of cells 
suggest a differentiation pattern similar to that observed in neuro-endocrine differentiation, 
which further indicates the repression of AR by LCoR. This experiment indicates that 
corepressor function is important for inhibition of AR and thereby the growth of CaP cells.  
 
5.7.2 Combinatorial effect of agonist R1881 and Src inhibition on CaP growth 
 
Overexpression of LCoR in androgen-independently growing C4-2 cells leads to a 
decrease in colony number (fig. 5.28). Src inhibition by a specific chemical inhibitor leads 
to enhanced in vivo binding of LCoR with AR and also strengthens its autonomous 
repression potential thereby allowing AR to be more robustly repressed in C4-2 cells (sec. 
5.6). To test the effect of enhanced AR repression by LCoR under the influence of Src 
inhibition, another colony formation assay was performed in androgen-depleted T-media. 
Briefly, 500.000 C4-2 cells were seeded out in 10 cm tissue culture dishes and were 
cotransfected with or without pSG5-LCoR together with PETE. Cells were selected over a 
period of 8 weeks on hygromycin (200 µg/ml) with regular exchange of fresh media twice 
weekly. Cells growing under no hormone “control” conditions show decreased growth and 
smaller colonies (Fig. 5.29). Notably, cells transfected with LCoR showed less cells per 
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colony compared to the cells transfected with empty vector control. However, R1881 
treatment led to a growth acceleration and formation of cellular foci in both, cells treated  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.29 Cotreatment of LCoR expressing C4-2 cells with PP2 and R1881 represses growth. 
Photomicrographs of C4-2 cells stably expressing empty vector control or LCoR. 500.000 C4-2 
cells were grown in T-medium containing androgen-depleted serum. Cells were transfected with 
pSG5 empty vector or pSG5-LCoR along with pETE vector in 5:1 molar ratio employing calcium 
phosphate transfection protocol. Cells were selected with 200 µg/ml hygromycin over a period of 8 
weeks with continuous fresh media change twice a week.  
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with empty vector control and in LCoR-transfected cells (Fig. 5.29). Interestingly no 
decrease either in cell number or in colony number was observed (Fig. 5.30), suggesting 
that LCoR may require some of the components such as growth factors present in the 
normal serum containing media to allow long-term repressional effect on cellular growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.30 PP2-mediated blockade of Src kinase enhances growth inhibitory effect of LCoR in 
C4-2 cells. 500.000 C4-2 cells stably expressing empty vector control or LCoR, were grown in T-
medium containing androgen-depleted serum. Cells were transfected with pSG5 empty vector or 
pSG5-LCoR along with pETE vector in 5:1 molar ratio employing calcium phosphate transfection 
protocol. Cells were selected with 200 µg/ml hygromycin over a period of 8 weeks with continuous 
fresh media change twice a week. C4-2 cells were numbered for the colonies formed. Average of 
duplicate was taken and the graph was plotted.  
 
Treatment of cotransfected cells with PP2 however led to a drastic decrease in cell number, 
intriguingly there were more colonies compared to no hormone control conditions (Fig. 
5.29 & 5.30). This data is in line with the results showing the growth inhibitory effect of 
Src blockade on cellular growth (sec. 5.3 fig. 5.8). Co treatment of cells with PP2 and 
R1881 resulted in decrease both in cellular growth and colony number (Fig. 5.29 & 5.30). 
Data suggest that C4-2 cells stably transfected with LCoR show growth retardation in 
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response to long-term cotreatment with agonist R1881 and Src inhibitor PP2. This implies 
that LCoR function to repress CaP cellular growth indeed is subject to attenuation by Src 
signal transduction pathway and that androgen-independently growing C4-2 cells depend 
on AR activity for survival and growth. 
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6. Discussion 
 
6.1 Modulation and functional consequence of AR recruitment on PSCA and PSA 
target genes 
 
AR is the biological mediator of androgen action. Recruitment of AR on target genes 
results in either transcriptional activation or transcriptional repression. This involves the 
tight regulation of AR function by coactivators and corepressors. Corepressors are 
recruited to anti-hormone CPA-bound AR and lead to the repression of target gene 
expression (Dotzlaw et al., 2002). AR mediated activation of target genes is generally seen 
as a growth promotion strategy by CaP cells. Recently PSCA was identified as a cell 
surface marker which is overexpressed in CaP. PSCA is an androgen-regulated gene and 
transient transfections involving PSCA-Luc have demonstrated strong induction of reporter 
in a ligand-dependent manner in non-CaP cells. To test whether AR ligands regulate 
physical interaction of AR and corepressors Alien and SMRT on PSCA target gene in CaP 
cells ChIP experiment was performed. For the first time these results indicate that, ligands 
differentially regulate the recruitment of AR on PSCA enhancer containing an ARE in 
vivo. In LNCaP cells, AR is recruited to PSCA enhancer in response to agonistic ligand 
R1881 (Fig. 5.1), similar effect were seen with the positive control PSA suggesting that 
PSCA acts also as a model gene to test direct AR action as PSA. Agonist R1881 also leads 
to loss of corepressor SMRT recruitment on both the enhancers. Treatment of LNCaP cells 
with partial agonistic ligand CPA leads to robust recruitment of corepressor Alien and 
regain of SMRT recruitment on both PSA and PSCA enhancer in line with previous report 
suggesting enhanced binding of SMRT and Alien to CPA-bound AR in mammalian-one-
hybrid assay (Dotzlaw et al., 2002). Casodex leads to a steep decrease in AR recruitment to 
PSA enhancer in line with a recent report suggesting that Cas interferes with the stable 
DNA binding of AR (Farla et al., 2005). However, this can not be a general effect of Cas 
on AR as the recruitment of AR is seen on PSCA enhanced under similar conditions in 
LNCaP cells. It is possible that Cas-mediated prevention of AR from stably recruiting to 
DNA elements may in part dictated by response element thereby adding further intricacy to 
the regulation of target gene expression. ChIP experiment in C4-2 cells indicates a robust 
recruitment of AR even in the absence of agonist suggesting AR activation by autocrine 
growth loops and possibly by signal transduction cascades. No changes either in the 
recruitment of corepressor Alien or SMRT were observed under all experimental 
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conditions except a decrease in AR recruitment in the presence of Cas. This suggest that 
AR may be constitutively active on its target genes allowing them to grow in an androgen-
independent manner, however, transient transfections revealed that indeed AR 
transactivation function is modulated by various ligands suggesting that in C4-2 cells the 
activity of AR might be regulated by some other unknown corepressors which might be 
differentially recruited to regulate AR function in C4-2 cells. In fact, treatment of C4-2 
cells with CPA leads to a decrease in PSCA mRNA (sec. 5.2.3 fig. 5.3) emphasizing the 
regulation of constitutively recruited AR by ligands which may potentially function by to 
date unidentified corepressors. 
 
6.2 negative regulation of maspin by AR in CaP cells 
 
Maspin is a member of serine protease family and is a tumour suppressor and inhibits 
tumour progression (Cher et al., 2003). Interestingly the expression of maspin is known to 
be down-regulated by androgens (Zhang et al., 1997), however evidence for a molecular 
mechanism of direct regulation of maspin by AR transactivation function are lacking. Till 
date there are no reports on how this negative regulation works for the AR target gene 
exist. For the first time, ChIP in LNCaP and C4-2 CaP cells show recruitment of AR and 
corepressor Alien and SMRT on maspin promoter (sec. 5.2.2) raising a possibility that its 
expression may be subject to direct regulation by AR and the tested corepressors SMRT 
and Alien. Under conditions of no hormone treatment (referred as control), AR is recruited 
to maspin possibly repressing its expression in order to promote cell invasion. Corepressor 
Alien seems to play an important role in the AR recruitment mediated repression of 
maspin, which is co-recruited with SMRT and also alone on maspin under conditions of no 
hormone in C4-2 and LNCaP cells respectively. Interestingly, the binding of AR is 
decreased or completely lost in presence of agonist R1881 or partial agonist CPA in both 
cell lines. This suggests that the response elements itself in part governs the recruitment of 
AR, by allowing unliganded or non-cognate ligand bound confirmation to be stable to 
DNA (as seen without hormone), while, preventing the stable DNA binding of agonist 
R1881 or CPA bound AR further indicating the role of corepressor Alien in allowing 
maspin gene to remain under repressed state in CaP cells. CPA treatment in addition to 
decreasing AR recruitment on maspin, also lead to a sharp decrease in Alien recruitment 
suggesting that the DNA-AR-CPA conformation may be inhibitory to Alien recruitment. 
To test the functional implications of decreased AR and Alien binding on maspin 
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promoter, real time experiments were performed, which indicated enhanced maspin mRNA 
expression by CPA treatment (sec. 5.2.3 fig. 5.3). Taken together, these results suggest that 
(1) Negative-regulation of target gene expression is a phenomenon not restricted to TR and 
RAR only (2) AR recruitment on the negative response element is dictated in part by the 
nature of the cis-DNA element possibly by allowing different AR conformations than 
observed on a positive element to stably bind to it (3) negative regulation might function 
by corepressors differentially recruited in response to various ligands. This also suggests 
that on a negative response element CPA- bound AR does not allow robust binding of 
Alien. 
 
6.3 Cell type-specific regulation of corepressor SMRT interaction with AR in CaP 
cells 
 
Eukaryotic transcription factors can exert both positive and negative effects on gene 
expression. Activity of corepressors is also subject to regulation in turn by signal 
transduction cascades, allowing an indirect effect on the activity of NRs. CaP cells, like 
other cancer cells device many cellular alterations that combinely, or synergistically result 
in their faster growth and escape from therapeutic intervention. As evident, AR repression 
by corepressors hold a great promise, which have been shown to therapeutic anti-hormone 
bound AR leading to target gene repression. It is possible that in order to overcome effects 
of anti-hormone therapy, CaP may specifically inactivate corepressor SMRT which 
interacts with antihormone bound AR (Dotzlaw et al., 2002). In other cells types 
corepressor SMRT and CtBP have been shown to be functionally inactivated by cellular 
signaling pathways (Hong and Privalsky 1998, 2000, Barnes et al., 2003). To test whether 
signaling kinases can also affect the ability to corepressor SMRT in repressing AR 
function, mammalian-one-hybrid assays have been performed to test the modulation of 
interaction of endogenous AR in LNCaP and C4-2 cells in vivo. On testing, a wide 
spectrum of inhibitors found that the binding of SMRT is regulated by MAPK pathway and 
its specific blockade by its inhibitor U0126 leads to enhanced interaction of SMRT with 
AR mutant found in LNCaP cells (Fig. 5.10 C). This data is in line with a previous report 
showing that tyrosine kinases negatively regulate SMRT interaction with TR, another 
member of NR superfamily (Hong et al., 1998). In addition, protein kinase C-related kinase 
(PRK1) is known to be overexpressed in CaP cells, shown to enhance AR transactivation 
function by potentiating TAU-5 function and have been  implicated in CaP progression 
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(Metzger et al., 2003). In line with this blocking PRK1 by HA1077, its specific inhibitor, 
leads to a significant increase in SMRT AR interaction in LNCaP (Fig. 5.10 B) but not in 
C4-2 cells (Fig. 5.11 B) suggesting that AR SMRT interaction in C4-2 cells is not 
regulated by PRK1 signaling and may potentially involve other signaling cascades which 
might impart androgen-independently growing properties to these cells (Unni et al., 2004). 
This also suggests that PRK1-mediated enhancement of AR transactivation (Metzger et al., 
2003) may in part involve loss of physical interaction and potentially its functional 
inactivation to repress AR function in vivo. In contrast, AR transactivation in C4-2 remains 
unaffected by blockade of PRK1 (Fig. 5.11 B) further highlight the molecular differences 
between the signaling pathways in regulating interaction of SMRT with AR within the two 
cell lines.  
This suggest that androgen-dependently and androgen-independently growing cells may 
specifically use different subset of signal transduction pathways to regulate SMRT function 
rather than the notion that increasing number of signal transduction pathways are 
overexpressed with the transition of CaP to an androgen-independent state.  
Interestingly, SMRT binds to AR in vivo in C4-2 cells without blocking any specific signal 
transduction pathway (Fig. 5.11 A) , however this binding is not observed in LNCaP cells 
(Fig. 5.10 A) indicating that SMRT is more functionally active in C4-2 cells compared to 
LNCaP cells. Indeed enhanced levels of SMRT in CaP cells have been correlated with 
repression of target genes associated with antiproliferative action (Khanim et al., 2004) and 
may thereby provide a growth promoting strategy to androgen-independently growing C4-
2 cells. To test the implication of enhanced SMRT interaction in LNCaP cells by blocking 
MAPK, Src and PRK-1, functional experiments, with f.l. SMRT on AR function are 
sought. Our preliminary results with ectopic expression of SMRT in LNCaP cells and 
cotreatment with U0126 MAPK inhibitor indicate a more robust effect of corepressor 
SMRT in repressing AR function in LNCaP cells (Michael Eisold, Diploma thesis). 
Results obtained from stably integrated SMRT from colony formation experiments done to 
test the effect of SMRT and MAPK blockade on the growth of LNCaP cells also indicate a 
dramatic decrease in colony number in U0126 and CPA-dependent manner.  
The influence of tyrosine kinase blockade on SMRT and AR interaction was also tested in 
LNCaP and C4-2 cells. In LNCaP cells, SMRT binding was not influenced by tyrosine 
kinase inhibitor AG1517 (Fig. 5.10 D), however similar experiment in C4-2 cells led to the 
loss of SMRT interaction with AR (Fig. 5.11 D). It implies that signaling kinases do not 
always lead to loss of corepressor function rather in some cases they may rather potentiate 
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their effect. In C4-2 cells, SMRT interaction is decreased with AR by blocking receptor 
tyrosine kinases. Results from mammalian-one hybrid experiment suggest that the binding 
of SMRT to AR is subject to modulation by other kinases as well. Using PP2 the chemical 
inhibitor of Src kinase pathway, the interaction is enhanced in a CPA-dependent manner in 
vivo, suggesting that Src kinase pathway may negatively influence binding of corepressor 
SMRT with AR and may potentially be involved thereby in activating AR function. 
Because Src kinase also acts through MAPK as well, it is possible that the U0126-mediated 
enhancement of SMRT interaction with AR observed by blocking MAPK may be a result 
of blockade of Src kinase situated upstream of MAPK. Results from mammalian-one-
hybrid performed in C4-2 cells suggest that signaling pathways that lead to decreased 
SMRT binding in LNCaP cells are ineffective in regulating this interaction suggesting this 
interaction to be a cell type specific phenomenon. 
 
6.4 Src kinase provides a growth promotion strategy to androgen-independently 
growing cells 
 
As discussed in section 2.3, AR activation in addition to mutations, is attributed to signal 
transduction pathways. Signal transduction pathways are over expressed in many types of 
cancers and lead to therapy failure including for breast carcinoma. Src, a non-receptor 
tyrosine kinase is activated in breast carcinoma and leads to the failure of antagonist 
Tamoxifen-based therapy by allowing it to function as a potent agonist (Shah et al., 2005). 
The role of Src kinase in regulating androgen-independent growth was tested in C4-2 cells. 
Src kinase inhibitor PP2 leads to the decreased AR transactivation on two different 
response elements (Sec. 5.3.1 fig. 5.4), however the transcription from a control gene 
pCMV-LacZ remains unaffected (Fig. 5.5). It is notable that the AR transactivation seen in 
fig. 5.4 is contributed by androgens and growth factors. ChIP experiments done to correlate 
decreased reporter activity to AR transactivation and recruitment indicated a basal AR 
recruitment in the absence of hormone (Fig. 5.6). The recruitment is further enhanced 
when cells were treated with agonist R1881. Part of the result is in concordance with 
section 5.2.1 that AR is recruited to PSA enhancer in the absence of agonistic ligand which 
is attributed to its cross-talk and possible activation by other non-cognate ligands as a 
result of broadened specificity. Src blockade, however dramatically reduced the 
recruitment of AR in the absence of R1881, which strengthens the idea of agonist-
independent recruitment of AR to PSA enhancer, is indeed a result of its cross talk with 
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signal transduction pathways. Surprisingly, R1881 overcomes the effect of decreased AR 
recruitment by PP2.  
The real-time experiment performed to test and to correlate the transient transfections and 
ChIP (Sec. 5.3.3 fig. 5.7). Taken together, these results indicate that AR is recruited to a 
certain degree independent of androgens to its target genes. C4-2 cells also express PSA at 
a basal level, which could be attributed to the androgen-independent marginal recruitment 
of AR allowing the expression of PSA, in addition, one report suggest that PSA basal 
expression in androgen-independently growing cells does not requires AR binding (Jia et 
al., 2005). However, induction of PSA mRNA by R1881 does require enhanced AR 
binding (fig. 5.7). This induction of AR-mediated PSA expression may require Src kinase 
signaling blocking which, leads to decreased target gene expression as evident from 
reporter assay (Fig. 5.4) and from real time PSA expression analysis. Long-term PP2 
treatment leads to growth inhibition of C4-2 cells in androgen-containing growth factor 
rich T-media, suggesting that PP2-mediated Src blockade not only affects induction of 
target gene expression, rather leads to decreased growth of C4-2 cells presumably by 
interfering with the expression of target genes which play important function in cell cycle. 
 
6.5 LCoR interacts with the DBD of AR in a hormone-dependent fashion 
 
LCoR was initially identified in screen for proteins that interacted with the LBD of ERα in 
a hormone-dependent manner (Fernandes et al., 2003). The C-terminus of LCoR, 
harbouring an HLH interaction motif and devoiding of a NR box exhibited a CPA-
dependent interaction with AR (Michaela Patz, Diploma thesis). As for other members of 
NHR superfamily, NR box interacts with the helix-12 in the LBD in a ligand-dependent 
manner; it raised the possibility that LBD may not be involved in interaction with LCoR. 
Indeed, these speculations turned out to be correct when various N-terminal and LBD-
mutants of AR were robustly repressed by LCoR w.t. or in the similar way by LCoR-NR 
box mutant (sec. 5.5.5 fig. 5.19 & 5.20). Another hybrid mutant of AR, where NTD was 
replaced by VP16 transactivation domain was used to find out if N-terminus is not targeted 
by LCoR (Fig. 5.21 B). This data suggested that LCoR does not target the NTD. Later 
experiment with VP16-DBD confirmed that LCoR targets the DBD of AR. (Sec. 5.5.5 fig. 
5.22). This data suggest that LCoR specifically targets the DBD of AR. It raises two 
possibilities explaining the repression of AR transactivation. Either LCoR binding to DBD 
may interfere with the recognition of AREs by the DBD thereby preventing stable binding 
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of AR to cognate response elements. Another possibility is that DBD-bound LCoR may 
recruit HDAC or CtBP silencing machinery to DBD thereby repressing AR mediated 
transactivation. Solution to this enigma comes from the mammalian-one-hybrid studies. 
The results obtained from these studies clearly indicate that the binding of VP16-cLCoR 
with AR can be enhanced several folds in a CPA or R1881-dependent manner (Sec. 5.5.3 
fig. 5.17). Had there been a displacement of AR through its DBD by LCoR, this enhanced 
interaction could not be realised. In fact the second Zn finger present in the DBD of AR 
which has been shown to assist interaction with coregulatory proteins (O’ Malley, 1990) is 
highly conserved among different members of NHR superfamily. Agonist-dependent 
repression of LCoR suggests that LCoR may be a part of negative feedback loop in AR 
transactivation presumably by (co)competing with coactivators and thereby fine-regulating 
the AR transactivation. 
 
6.6 Functional attenuation of LCoR in androgen-independent prostate cancer 
 
The question arises why potent corepressors which are expressed in CaP allow AR to 
remain superactive in CaP cells. It is possible that ratio of coactivators to corepressors, 
which has been shown to be high in CaP cells (Liu et al., 2004) gives competitive 
advantage to coactivators to bind to AR in CaP cells. This increase in ratio of coactivators 
to corepression may arise from (1) the overexpression of coactivators or decreased 
expression of corepressors or (2) functional attenuation of corepressors by signal 
transduction pathways which are known to be activated in CaP cells.  
Also there are many signaling pathways known to be hyperactivated in CaP cells (sec 2.4) 
and as coregulatory proteins are phosphorylation target by many of these abruptly activated 
pathways it is possible that LCoR may be functionally attenuated by phosphorylation and 
may therefore not be able to repress AR function in CaP cells as strongly as seen in CV1 
cells (Fig. 5.14). Therefore, a battery of specific chemical inhibitors was screened for 
identification of possible involvement of specific signaling cascades, which may 
phosphorylate and thereby attenuate LCoR repression function. The results of signaling 
inhibition experiments to test LCoR ability to repress AR indicate the involvement of a 
specific tyrosine kinase called Src. Indeed a member of Src family, called FAK (focal 
adhesion kinase) is known to be overexpressed in CaP cells (Slack et al., 2001,) and its 
expression is continued during the progression of CaP (Rovin et al., 2002). Utilising 
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specific inhibitor called PP2 for blocking this pathway; it is possible to enhance the 
repression potential of LCoR and thereby enhancing its repressive effect on AR. 
 
6.7 Model  
 
 
 
 
 
 
 
 
 
 
Fig. 6.1 LCoR is expressed in normal prostate and represses target gene transcription in a 
hormone-dependent manner. Over expression of Src kinase leads to functional attenuation 
of LCoR to interact with and to repress AR function and thereby giving a competitive 
advantage to coactivators to enhance AR function and the growth of CaP cells.  
 
 
7. Outlook 
 
A diverse array of AR target genes has been identified. The molecular mechanism for the 
upregulation of target gene expression has been very well explored. However, target genes 
such as maspin, downregulate in response to androgens. The mechanism to explain 
negative regulation by androgens in only poorly understood and the involvement of AR 
and its corepressors is not clear. Important goal here would be to find out how in presence 
of various agonists, the expression of maspin varies and how exactly AR is involved in 
repressing maspin expression. TR is known to recruit corepressors in the absence of 
cognate ligand and repress target gene function. Similarly, in context of maspin the role of 
AR needs to be explored. Another possibility is the recruitment of corepressors to AR on 
target genes, which may also account for target gene repression. AR knock down would be 
important here to test direct regulation by AR. 
Corepressor LCoR represses growth of androgen-independently growing C4-2 cells and 
LCoR-mediated AR repression can be boosted by blocking Src kinase signaling by 
chemical inhibitor PP2. The question is how the potentiation of LCoR function modulates 
Model depicting attenuation of LCoR repression function in repressing AR 
transactivation  in prostate carcinoma
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the expression of endogenous target genes in C4-2 and LNCaP cells. To test this, real-time 
PCR experiments can be carried out to ascertain (1) the influence of LCoR on target gene 
expression (2) Influence of Src blockade upon target gene expression. Also, a ChIP 
experiment would be important to test the whether LCoR is ligand-dependently recruited 
on AR at target genes. In addition, to test the combinatorial effect of LCoR and Src 
blockade, colony formation experiments with C4-2 cells are required. Because, Src and 
LCoR individually repress the growth of C4-2 cells, an enhanced combinatorial effect is 
envisaged. In addition Xenografts of C4-2 cells, stably overexpressing LCoR can be grown 
in nude mice to test the influence of corepressor LCoR on the growth of cancer in vivo. 
LCoR sequence analyses show many potential tyrosine and ser/thr kinase phosphorylation 
sites suggesting that LCoR may be phosphorylated by other signaling cascades as well in 
addition to Src. Blockade of Src leads to decrease in AR transactivation and decreased 
growth of C4-2 cells, suggesting that Src may contribute to hormone-independent AR 
activation in C4-2 cells. Here a CaP cell line engineered to over express Src will be 
generated and their growth sensitivity will be tested for various ligands, in addition, 
xenografts will be generated in nude mice to test their growth behavior and sensitivity to 
regression upon anti-hormone administration. 
 At this point importance of individual corepressors in regulating AR function is largely 
lacking. Further work in this direction should elaborate the role of AR corepressors 
specifically SMRT, NCoR, Alien and LCoR in regulating AR function and thereby cellular 
growth in normal prostate cells and CaP cells. RNAi-mediated individual corepressor 
knock down will reveal the functional significance of each of these corepressors in 
regulating the expression of both positively and negatively regulated genes and in turn 
regulating CaP growth.  
As has been emphasized through out the study, activation of signal transduction pathway 
plays an important role in inactivating corepressor. However at this point cell type over 
expression of specific signaling molecules remains largely unexplored. In this direction, 
differential kinome expression in normal and malignant prostate cells can be ascertained by 
protein-ChIP based analyses as well as by DNA microarray to detect difference in kinome 
expression. This would be instrumental in developing effective and more precisely tailored 
drugs based on the signal transduction inhibitors, against CaP. These findings will also be 
important in finding out new signal transduction pathways that lead to corepressor 
inactivation.  
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Also there is a great thrust in finding new target genes which play important role in CaP 
progression and its metastasis. In the last decade, over 2 dozens of androgen-regulated 
genes have been found, employing reporter assays and electrophoretic mobility shift 
assays. Regulation of many of those however, does not entirely correlate with the 
aggressive behaviour of the disease and failure of anti-hormone therapy. In order to find 
out new androgen target genes ChIP on Chip assay can be performed to find out new target 
genes of androgens. In addition microarray-based studies could be proven effective in 
finding target genes which are negatively modulated by androgens.  
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